Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	cell adhesion molecule binding	ANK3 SPTBN2 ICAM3 ITGA8 LAMB2 CPE LILRB1 MFGE8 BAIAP2L1 NRXN2 TLN1 DCHS1 SDCBP	1.26e-05	599	103	13	GO:0050839
GeneOntologyMolecularFunction	H3K27me3 modified histone binding	TAF1 TAF1L	2.61e-04	5	103	2	GO:0061628
GeneOntologyMolecularFunction	RNA polymerase II core promoter sequence-specific DNA binding	RFX7 TAF1 TAF1L	2.82e-04	25	103	3	GO:0000979
GeneOntologyBiologicalProcess	cell-cell adhesion	MIA3 IL18 ANK3 DUSP3 ICAM3 PCDHB10 ITGA8 LILRB1 FBXO38 HMCN1 BAIAP2L1 NRXN2 PPM1F TLN1 DHPS DCHS1 ASTN1 PCDH1	7.75e-06	1077	105	18	GO:0098609
GeneOntologyBiologicalProcess	positive regulation of cellular response to transforming growth factor beta stimulus	CDKN1C CDKN2B ITGA8 SDCBP	2.94e-05	35	105	4	GO:1903846
GeneOntologyBiologicalProcess	positive regulation of transforming growth factor beta receptor signaling pathway	CDKN1C CDKN2B ITGA8 SDCBP	2.94e-05	35	105	4	GO:0030511
GeneOntologyCellularComponent	proteasome accessory complex	PSMC2 PSMD4 PSMD13 PSME1	7.28e-06	25	106	4	GO:0022624
GeneOntologyCellularComponent	proteasome regulatory particle	PSMC2 PSMD4 PSMD13	1.82e-04	22	106	3	GO:0005838
GeneOntologyCellularComponent	proteasome complex	PSMC2 PSMD4 PSMD13 PSME1	3.75e-04	67	106	4	GO:0000502
GeneOntologyCellularComponent	secretory vesicle	MPO LILRB3 HK3 SPTBN2 PSMC2 CPE PSMD13 EPX RAB44 MYOF MFGE8 CLTC ALDH3B1 RAB2A SERPINA5 SDCBP	5.29e-04	1246	106	16	GO:0099503
Domain	TFIID_sub1_DUF3591	TAF1 TAF1L	2.90e-05	2	101	2	IPR022591
Domain	TBP-binding	TAF1 TAF1L	2.90e-05	2	101	2	PF09247
Domain	DUF3591	TAF1 TAF1L	2.90e-05	2	101	2	PF12157
Domain	TAF_II_230-bd	TAF1 TAF1L	2.90e-05	2	101	2	IPR009067
Domain	-	TAF1 TAF1L	2.90e-05	2	101	2	1.10.1100.10
Domain	TAF1_animal	TAF1 TAF1L	2.90e-05	2	101	2	IPR011177
Domain	Bromodomain_CS	BRPF3 TAF1 TAF1L	3.65e-04	26	101	3	IPR018359
Domain	PEROXIDASE_1	MPO EPX	4.28e-04	6	101	2	PS00435
Pathway	REACTOME_MITOTIC_G1_PHASE_AND_G1_S_TRANSITION	CDKN1C CDKN2B PSMC2 PSMD4 PSMD13 PSME1	1.16e-04	130	83	6	MM15146
Pathway	REACTOME_PCP_CE_PATHWAY	PSMC2 PSMD4 PSMD13 PSME1 CLTC	1.42e-04	85	83	5	MM15041
Pathway	KEGG_PROTEASOME	PSMC2 PSMD4 PSMD13 PSME1	1.51e-04	46	83	4	M10680
Pathway	REACTOME_C_TYPE_LECTIN_RECEPTORS_CLRS	ICAM3 PSMC2 PSMD4 PSMD13 PSME1 MUC5AC	1.74e-04	140	83	6	M27484
Pathway	REACTOME_CROSS_PRESENTATION_OF_SOLUBLE_EXOGENOUS_ANTIGENS_ENDOSOMES	PSMC2 PSMD4 PSMD13 PSME1	1.78e-04	48	83	4	MM14528
Pathway	REACTOME_PCP_CE_PATHWAY	PSMC2 PSMD4 PSMD13 PSME1 CLTC	2.06e-04	92	83	5	M27322
Pathway	REACTOME_REGULATION_OF_RUNX2_EXPRESSION_AND_ACTIVITY	PSMC2 PSMD4 PSMD13 PSME1	2.09e-04	50	83	4	MM17068
Pathway	REACTOME_UBIQUITIN_MEDIATED_DEGRADATION_OF_PHOSPHORYLATED_CDC25A	PSMC2 PSMD4 PSMD13 PSME1	2.09e-04	50	83	4	MM15385
Pathway	REACTOME_CROSS_PRESENTATION_OF_SOLUBLE_EXOGENOUS_ANTIGENS_ENDOSOMES	PSMC2 PSMD4 PSMD13 PSME1	2.09e-04	50	83	4	M510
Pathway	REACTOME_MITOTIC_G1_PHASE_AND_G1_S_TRANSITION	CDKN1C CDKN2B PSMC2 PSMD4 PSMD13 PSME1	2.44e-04	149	83	6	M848
Pathway	REACTOME_REGULATION_OF_RUNX3_EXPRESSION_AND_ACTIVITY	PSMC2 PSMD4 PSMD13 PSME1	2.44e-04	52	83	4	MM15536
Pathway	REACTOME_NUCLEAR_EVENTS_MEDIATED_BY_NFE2L2	PSMC2 PSMD4 PSMD13 PSME1	2.63e-04	53	83	4	MM16640
Pathway	REACTOME_DEGRADATION_OF_AXIN	PSMC2 PSMD4 PSMD13 PSME1	2.63e-04	53	83	4	MM15152
Pathway	REACTOME_STABILIZATION_OF_P53	PSMC2 PSMD4 PSMD13 PSME1	2.82e-04	54	83	4	MM15384
Pathway	REACTOME_NEGATIVE_REGULATION_OF_NOTCH4_SIGNALING	PSMC2 PSMD4 PSMD13 PSME1	2.82e-04	54	83	4	M27931
Pathway	REACTOME_ABC_FAMILY_PROTEINS_MEDIATED_TRANSPORT	ABCA4 PSMC2 PSMD4 PSMD13 PSME1	2.91e-04	99	83	5	MM14986
Pathway	REACTOME_SOMITOGENESIS	PSMC2 PSMD4 PSMD13 PSME1	3.03e-04	55	83	4	M48032
Pathway	REACTOME_DEGRADATION_OF_AXIN	PSMC2 PSMD4 PSMD13 PSME1	3.03e-04	55	83	4	M27398
Pathway	REACTOME_REGULATION_OF_RUNX3_EXPRESSION_AND_ACTIVITY	PSMC2 PSMD4 PSMD13 PSME1	3.03e-04	55	83	4	M27809
Pathway	REACTOME_AUF1_HNRNP_D0_BINDS_AND_DESTABILIZES_MRNA	PSMC2 PSMD4 PSMD13 PSME1	3.03e-04	55	83	4	MM15137
Pathway	REACTOME_DEGRADATION_OF_DVL	PSMC2 PSMD4 PSMD13 PSME1	3.03e-04	55	83	4	MM15153
Pathway	REACTOME_SCF_BETA_TRCP_MEDIATED_DEGRADATION_OF_EMI1	PSMC2 PSMD4 PSMD13 PSME1	3.03e-04	55	83	4	M17095
Pathway	REACTOME_AUF1_HNRNP_D0_BINDS_AND_DESTABILIZES_MRNA	PSMC2 PSMD4 PSMD13 PSME1	3.03e-04	55	83	4	M998
Pathway	WP_PROTEASOME_DEGRADATION	PSMC2 PSMD4 PSMD13 PSME1	3.25e-04	56	83	4	MM15901
Pathway	REACTOME_DECTIN_1_MEDIATED_NONCANONICAL_NF_KB_SIGNALING	PSMC2 PSMD4 PSMD13 PSME1	3.25e-04	56	83	4	MM15203
Pathway	REACTOME_DEGRADATION_OF_DVL	PSMC2 PSMD4 PSMD13 PSME1	3.48e-04	57	83	4	M27399
Pathway	REACTOME_STABILIZATION_OF_P53	PSMC2 PSMD4 PSMD13 PSME1	3.48e-04	57	83	4	M27670
Pathway	REACTOME_METABOLISM_OF_POLYAMINES	PSMC2 PSMD4 PSMD13 PSME1	3.48e-04	57	83	4	MM14955
Pathway	REACTOME_GLI3_IS_PROCESSED_TO_GLI3R_BY_THE_PROTEASOME	PSMC2 PSMD4 PSMD13 PSME1	3.48e-04	57	83	4	MM15205
Pathway	REACTOME_ABC_FAMILY_PROTEINS_MEDIATED_TRANSPORT	ABCA4 PSMC2 PSMD4 PSMD13 PSME1	3.49e-04	103	83	5	M758
Pathway	REACTOME_SCF_SKP2_MEDIATED_DEGRADATION_OF_P27_P21	PSMC2 PSMD4 PSMD13 PSME1	3.72e-04	58	83	4	MM14715
Pathway	REACTOME_METABOLISM_OF_POLYAMINES	PSMC2 PSMD4 PSMD13 PSME1	3.97e-04	59	83	4	M747
Pathway	REACTOME_SCF_SKP2_MEDIATED_DEGRADATION_OF_P27_P21	PSMC2 PSMD4 PSMD13 PSME1	4.24e-04	60	83	4	M1081
Pathway	REACTOME_DEGRADATION_OF_GLI1_BY_THE_PROTEASOME	PSMC2 PSMD4 PSMD13 PSME1	4.24e-04	60	83	4	M27470
Pathway	REACTOME_ASYMMETRIC_LOCALIZATION_OF_PCP_PROTEINS	PSMC2 PSMD4 PSMD13 PSME1	4.24e-04	60	83	4	MM15150
Pathway	REACTOME_DEFECTIVE_CFTR_CAUSES_CYSTIC_FIBROSIS	PSMC2 PSMD4 PSMD13 PSME1	4.52e-04	61	83	4	M27563
Pathway	REACTOME_TRANSCRIPTIONAL_REGULATION_BY_RUNX2	PSMC2 PSMD4 PSMD13 PSME1	4.81e-04	62	83	4	MM15521
Pathway	WP_PROTEASOME_DEGRADATION	PSMC2 PSMD4 PSMD13 PSME1	4.81e-04	62	83	4	M39639
Pathway	REACTOME_DECTIN_1_MEDIATED_NONCANONICAL_NF_KB_SIGNALING	PSMC2 PSMD4 PSMD13 PSME1	4.81e-04	62	83	4	M27465
Pathway	REACTOME_HEDGEHOG_LIGAND_BIOGENESIS	PSMC2 PSMD4 PSMD13 PSME1	4.81e-04	62	83	4	MM15181
Pathway	REACTOME_ACTIVATION_OF_NF_KAPPAB_IN_B_CELLS	PSMC2 PSMD4 PSMD13 PSME1	4.81e-04	62	83	4	MM14514
Pathway	REACTOME_NERVOUS_SYSTEM_DEVELOPMENT	RPS6KA4 ANK3 SPTBN2 PSMC2 PSMD4 PSMD13 PSME1 MYH14 TLN1 CLTC SDCBP	5.30e-04	575	83	11	M29853
Pathway	REACTOME_ASYMMETRIC_LOCALIZATION_OF_PCP_PROTEINS	PSMC2 PSMD4 PSMD13 PSME1	5.43e-04	64	83	4	M27396
Pathway	REACTOME_G1_S_DNA_DAMAGE_CHECKPOINTS	PSMC2 PSMD4 PSMD13 PSME1	5.43e-04	64	83	4	MM15386
Pathway	REACTOME_RUNX1_REGULATES_TRANSCRIPTION_OF_GENES_INVOLVED_IN_DIFFERENTIATION_OF_HSCS	PSMC2 PSMD4 PSMD13 PSME1	5.76e-04	65	83	4	MM15530
Pathway	REACTOME_HEDGEHOG_LIGAND_BIOGENESIS	PSMC2 PSMD4 PSMD13 PSME1	5.76e-04	65	83	4	M27439
Pathway	REACTOME_REGULATION_OF_RAS_BY_GAPS	PSMC2 PSMD4 PSMD13 PSME1	6.10e-04	66	83	4	MM15261
Pathway	REACTOME_INNATE_IMMUNE_SYSTEM	MPO LILRB3 HK3 DUSP3 PSMC2 PSMD4 PSMD13 PSME1 CPN1 EPX LILRB1 RAB44 STAT6 ALDH3B1 SDCBP	6.28e-04	995	83	15	MM14661
Pathway	REACTOME_REGULATION_OF_RAS_BY_GAPS	PSMC2 PSMD4 PSMD13 PSME1	6.83e-04	68	83	4	M27539
Pathway	REACTOME_G1_S_DNA_DAMAGE_CHECKPOINTS	PSMC2 PSMD4 PSMD13 PSME1	6.83e-04	68	83	4	M27672
Pathway	REACTOME_REGULATION_OF_PTEN_STABILITY_AND_ACTIVITY	PSMC2 PSMD4 PSMD13 PSME1	7.22e-04	69	83	4	MM15540
Pathway	REACTOME_ORC1_REMOVAL_FROM_CHROMATIN	PSMC2 PSMD4 PSMD13 PSME1	7.22e-04	69	83	4	MM15366
Pathway	REACTOME_REGULATION_OF_PTEN_STABILITY_AND_ACTIVITY	PSMC2 PSMD4 PSMD13 PSME1	7.22e-04	69	83	4	M27815
Pathway	REACTOME_CELLULAR_RESPONSE_TO_HYPOXIA	PSMC2 PSMD4 PSMD13 PSME1	7.22e-04	69	83	4	MM14522
Pathway	REACTOME_FORMATION_OF_PARAXIAL_MESODERM	PSMC2 PSMD4 PSMD13 PSME1	7.22e-04	69	83	4	M46439
Pathway	REACTOME_L1CAM_INTERACTIONS	RPS6KA4 ANK3 SPTBN2 CLTC SDCBP	7.30e-04	121	83	5	M872
Pathway	REACTOME_CYCLIN_A_CDK2_ASSOCIATED_EVENTS_AT_S_PHASE_ENTRY	PSMC2 PSMD4 PSMD13 PSME1	7.62e-04	70	83	4	MM15389
Pathway	REACTOME_INNATE_IMMUNE_SYSTEM	MPO LILRB3 HK3 DUSP3 ICAM3 PSMC2 PSMD4 PSMD13 PSME1 CPN1 EPX RAB44 STAT6 ALDH3B1 MUC5AC SDCBP	7.86e-04	1128	83	16	M1036
Pathway	REACTOME_INTERLEUKIN_1_FAMILY_SIGNALING	IL18 PSMC2 PSMD4 PSMD13 PSME1	7.86e-04	123	83	5	MM15125
Pathway	REACTOME_BETA_CATENIN_INDEPENDENT_WNT_SIGNALING	PSMC2 PSMD4 PSMD13 PSME1 CLTC	7.86e-04	123	83	5	MM14988
Pathway	REACTOME_CDK_MEDIATED_PHOSPHORYLATION_AND_REMOVAL_OF_CDC6	PSMC2 PSMD4 PSMD13 PSME1	8.04e-04	71	83	4	MM15370
Pathway	REACTOME_ORC1_REMOVAL_FROM_CHROMATIN	PSMC2 PSMD4 PSMD13 PSME1	8.04e-04	71	83	4	M4138
Pathway	REACTOME_NEUTROPHIL_DEGRANULATION	MPO LILRB3 HK3 PSMC2 PSMD13 EPX LILRB1 RAB44 ALDH3B1 SDCBP	8.12e-04	511	83	10	MM15330
Pathway	REACTOME_REGULATION_OF_RUNX2_EXPRESSION_AND_ACTIVITY	PSMC2 PSMD4 PSMD13 PSME1	8.48e-04	72	83	4	M27802
Pathway	REACTOME_THE_ROLE_OF_GTSE1_IN_G2_M_PROGRESSION_AFTER_G2_CHECKPOINT	PSMC2 PSMD4 PSMD13 PSME1	8.93e-04	73	83	4	MM15491
Pathway	REACTOME_MAPK6_MAPK4_SIGNALING	PSMC2 PSMD4 PSMD13 PSME1	8.93e-04	73	83	4	MM15285
Pathway	REACTOME_APC_C_CDH1_MEDIATED_DEGRADATION_OF_CDC20_AND_OTHER_APC_C_CDH1_TARGETED_PROTEINS_IN_LATE_MITOSIS_EARLY_G1	PSMC2 PSMD4 PSMD13 PSME1	9.40e-04	74	83	4	MM14678
Pathway	REACTOME_APC_C_CDH1_MEDIATED_DEGRADATION_OF_CDC20_AND_OTHER_APC_C_CDH1_TARGETED_PROTEINS_IN_LATE_MITOSIS_EARLY_G1	PSMC2 PSMD4 PSMD13 PSME1	9.40e-04	74	83	4	M1030
Pathway	REACTOME_CELLULAR_RESPONSE_TO_HYPOXIA	PSMC2 PSMD4 PSMD13 PSME1	9.88e-04	75	83	4	M641
Pathway	REACTOME_TRANSCRIPTIONAL_REGULATION_BY_RUNX3	PSMC2 PSMD4 PSMD13 PSME1	1.04e-03	76	83	4	MM15520
Pathway	REACTOME_ANTIGEN_PROCESSING_CROSS_PRESENTATION	PSMC2 PSMD4 PSMD13 PSME1	1.04e-03	76	83	4	MM14526
Pathway	REACTOME_ADAPTIVE_IMMUNE_SYSTEM	LILRB3 SPTBN2 ICAM3 LILRA6 PSMC2 PSMD4 TRIM71 PSMD13 PSME1 KLC4 LILRB1 CLTC HERC2	1.04e-03	828	83	13	M1058
Pathway	REACTOME_ACTIVATION_OF_APC_C_AND_APC_C_CDC20_MEDIATED_DEGRADATION_OF_MITOTIC_PROTEINS	PSMC2 PSMD4 PSMD13 PSME1	1.09e-03	77	83	4	MM14692
Pathway	REACTOME_KEAP1_NFE2L2_PATHWAY	PSMC2 PSMD4 PSMD13 PSME1	1.09e-03	77	83	4	MM15698
Pathway	REACTOME_DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR	PSMC2 PSMD4 PSMD13 PSME1	1.09e-03	77	83	4	MM14513
Pathway	REACTOME_ABC_TRANSPORTER_DISORDERS	PSMC2 PSMD4 PSMD13 PSME1	1.14e-03	78	83	4	M27473
Pathway	REACTOME_THE_ROLE_OF_GTSE1_IN_G2_M_PROGRESSION_AFTER_G2_CHECKPOINT	PSMC2 PSMD4 PSMD13 PSME1	1.20e-03	79	83	4	M27743
Pathway	REACTOME_DEGRADATION_OF_BETA_CATENIN_BY_THE_DESTRUCTION_COMPLEX	PSMC2 PSMD4 PSMD13 PSME1	1.20e-03	79	83	4	MM14754
Pathway	KEGG_MEDICUS_VARIANT_SCRAPIE_CONFORMATION_PRPSC_TO_26S_PROTEASOME_MEDIATED_PROTEIN_DEGRADATION	PSMC2 PSMD4 PSMD13	1.22e-03	36	83	3	M47758
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_ABETA_TO_26S_PROTEASOME_MEDIATED_PROTEIN_DEGRADATION	PSMC2 PSMD4 PSMD13	1.22e-03	36	83	3	M47713
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_HTT_TO_26S_PROTEASOME_MEDIATED_PROTEIN_DEGRADATION	PSMC2 PSMD4 PSMD13	1.22e-03	36	83	3	M47714
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_SNCA_TO_26S_PROTEASOME_MEDIATED_PROTEIN_DEGRADATION	PSMC2 PSMD4 PSMD13	1.22e-03	36	83	3	M47702
Pathway	REACTOME_ASSEMBLY_OF_THE_PRE_REPLICATIVE_COMPLEX	PSMC2 PSMD4 PSMD13 PSME1	1.32e-03	81	83	4	MM15360
Pathway	REACTOME_DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR	PSMC2 PSMD4 PSMD13 PSME1	1.32e-03	81	83	4	M595
Pathway	REACTOME_HEDGEHOG_ON_STATE	PSMC2 PSMD4 PSMD13 PSME1	1.32e-03	81	83	4	MM15225
Pathway	REACTOME_SIGNALING_BY_INTERLEUKINS	IL18 DUSP3 PSMC2 PSMD4 PSMD13 PSME1 STAT6	1.32e-03	281	83	7	MM15130
Pathway	REACTOME_SIGNALING_BY_NOTCH4	PSMC2 PSMD4 PSMD13 PSME1	1.38e-03	82	83	4	M594
Pathway	WP_STEROID_BIOSYNTHESIS	CYP17A1 CPN1	1.49e-03	10	83	2	M39538
Pathway	REACTOME_PROGRAMMED_CELL_DEATH	IL18 PSMC2 PSMD4 PSMD13 PSME1 SDCBP	1.52e-03	211	83	6	M27436
Pathway	REACTOME_G2_M_CHECKPOINTS	PSMC2 PSMD4 PSMD13 PSME1 HERC2	1.54e-03	143	83	5	MM15383
Pathway	KEGG_MEDICUS_REFERENCE_26S_PROTEASOME_MEDIATED_PROTEIN_DEGRADATION	PSMC2 PSMD4 PSMD13	1.54e-03	39	83	3	M47701
Pathway	REACTOME_CYCLIN_A_CDK2_ASSOCIATED_EVENTS_AT_S_PHASE_ENTRY	PSMC2 PSMD4 PSMD13 PSME1	1.57e-03	85	83	4	M27674
Pathway	REACTOME_DEGRADATION_OF_BETA_CATENIN_BY_THE_DESTRUCTION_COMPLEX	PSMC2 PSMD4 PSMD13 PSME1	1.57e-03	85	83	4	M27079
Pathway	REACTOME_REGULATION_OF_MRNA_STABILITY_BY_PROTEINS_THAT_BIND_AU_RICH_ELEMENTS	PSMC2 PSMD4 PSMD13 PSME1	1.64e-03	86	83	4	MM15140
Pathway	REACTOME_HEDGEHOG_ON_STATE	PSMC2 PSMD4 PSMD13 PSME1	1.64e-03	86	83	4	M27497
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_INACTIVATED_UBQLN2_TO_26S_PROTEASOME_MEDIATED_PROTEIN_DEGRADATION	PSMC2 PSMD4 PSMD13	1.66e-03	40	83	3	M47749
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_INACTIVATED_VCP_TO_26S_PROTEASOME_MEDIATED_PROTEIN_DEGRADATION	PSMC2 PSMD4 PSMD13	1.66e-03	40	83	3	M47748
Pathway	REACTOME_BETA_CATENIN_INDEPENDENT_WNT_SIGNALING	PSMC2 PSMD4 PSMD13 PSME1 CLTC	1.69e-03	146	83	5	M27288
Pathway	REACTOME_UCH_PROTEINASES	PSMC2 PSMD4 PSMD13 PSME1	1.72e-03	87	83	4	MM15287
Pathway	REACTOME_APC_C_MEDIATED_DEGRADATION_OF_CELL_CYCLE_PROTEINS	PSMC2 PSMD4 PSMD13 PSME1	1.72e-03	87	83	4	MM14677
Pubmed	Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.	NCOA2 ANK3 SPTBN2 PSMD4 PSME1 STAT6 FAN1 SH3YL1 CLIP4 MFGE8 MYH14 USP32 CLTC ASTN1 TAF1 WDFY3 HERC2 R3HDM1 TARBP1 SDCBP	2.18e-09	1285	107	20	35914814
Pubmed	Protein profile of exosomes from trabecular meshwork cells.	MYOF MFGE8 TLN1 CLTC SDCBP	4.29e-07	49	107	5	21362503
Pubmed	Inherent asymmetry in the 26S proteasome is defined by the ubiquitin receptor RPN13.	PSMC2 PSMD4 PSME1	5.62e-07	6	107	3	24429290
Pubmed	Phenotypic and Interaction Profiling of the Human Phosphatases Identifies Diverse Mitotic Regulators.	MIA3 ANK3 SPTBN2 PSMC2 PSMD4 PSMD13 PSME1 FAN1 FBXO38 MTMR4 PPM1F CLTC DHPS PPP1R18 HERC2	7.98e-07	1049	107	15	27880917
Pubmed	Identification and proteomic analysis of distinct UBE3A/E6AP protein complexes.	PSMC2 PSMD4 PSMD13 HERC2 PIPSL	1.01e-06	58	107	5	22645313
Pubmed	Discovery of a Human Testis-specific Protein Complex TEX101-DPEP3 and Selection of Its Disrupting Antibodies.	ISYNA1 PSMD13 PSME1 PAPSS2 MFGE8 MYH14 CLTC RAB2A	1.09e-06	249	107	8	30097533
Pubmed	CYLD Regulates Centriolar Satellites Proteostasis by Counteracting the E3 Ligase MIB1.	PSMD4 PSMD13 GRSF1 MYOF TLN1 CLTC HERC2	1.61e-06	182	107	7	31067453
Pubmed	Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function.	MPO IL18 ARHGAP23 PSMC2 PSMD4 CHD7 PSMD13 PAPSS2 GRSF1 ZGPAT MYH14 PPM1F TLN1 CLTC WDFY3 HERC2	3.89e-06	1353	107	16	29467282
Pubmed	Angelman syndrome-associated point mutations in the Zn2+-binding N-terminal (AZUL) domain of UBE3A ubiquitin ligase inhibit binding to the proteasome.	PSMC2 PSMD4 PSMD13 HERC2	4.12e-06	35	107	4	30257870
Pubmed	Characterization of Dynamic UbR-Proteasome Subcomplexes by In vivo Cross-linking (X) Assisted Bimolecular Tandem Affinity Purification (XBAP) and Label-free Quantitation.	PSMC2 PSMD4 PSMD13 PSME1 PIPSL	4.43e-06	78	107	5	27114451
Pubmed	Microarray analysis of Foxa2 mutant mouse embryos reveals novel gene expression and inductive roles for the gastrula organizer and its derivatives.	CDKN1C NPTX2 ANK3 CHD7 CPN1 RFX7 BAIAP2L1 ASTN1	5.02e-06	306	107	8	18973680
Pubmed	Structure and functions of the 20S and 26S proteasomes.	PSMC2 PSMD4 PSMD13 PSME1	5.17e-06	37	107	4	8811196
Pubmed	Hypermutation of HIV-1 DNA in the absence of the Vif protein.	PSMC2 PSMD4 PSMD13 PSME1	5.17e-06	37	107	4	12750511
Pubmed	An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein.	PSMC2 PSMD4 PSMD13 PSME1	5.17e-06	37	107	4	9811770
Pubmed	Evidence for a newly discovered cellular anti-HIV-1 phenotype.	PSMC2 PSMD4 PSMD13 PSME1	5.17e-06	37	107	4	9846577
Pubmed	Good to CU.	PSMC2 PSMD4 PSMD13 PSME1	5.17e-06	37	107	4	12840737
Pubmed	Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions.	PSMC2 PSMD4 PSMD13 PSME1	5.17e-06	37	107	4	12719574
Pubmed	Death by deamination: a novel host restriction system for HIV-1.	PSMC2 PSMD4 PSMD13 PSME1	5.17e-06	37	107	4	12914693
Pubmed	DNA deamination: not just a trigger for antibody diversification but also a mechanism for defense against retroviruses.	PSMC2 PSMD4 PSMD13 PSME1	5.17e-06	37	107	4	12830140
Pubmed	The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.	PSMC2 PSMD4 PSMD13 PSME1	5.77e-06	38	107	4	12808465
Pubmed	Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.	PSMC2 PSMD4 PSMD13 PSME1	5.77e-06	38	107	4	12808466
Pubmed	HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.	PSMC2 PSMD4 PSMD13 PSME1	5.77e-06	38	107	4	14527406
Pubmed	DNA deamination mediates innate immunity to retroviral infection.	PSMC2 PSMD4 PSMD13 PSME1	5.77e-06	38	107	4	12809610
Pubmed	The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.	PSMC2 PSMD4 PSMD13 PSME1	5.77e-06	38	107	4	14614829
Pubmed	Virology. Weapons of mutational destruction.	PSMC2 PSMD4 PSMD13 PSME1	5.77e-06	38	107	4	12920286
Pubmed	The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity.	PSMC2 PSMD4 PSMD13 PSME1	5.77e-06	38	107	4	12970355
Pubmed	Degradation of HIV-1 integrase by the N-end rule pathway.	PSMC2 PSMD4 PSMD13 PSME1	5.77e-06	38	107	4	10893419
Pubmed	The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.	PSMC2 PSMD4 PSMD13 PSME1	5.77e-06	38	107	4	14557625
Pubmed	Proteasome involvement in the repair of DNA double-strand breaks.	PSMC2 PSMD4 PSMD13	6.10e-06	12	107	3	15610744
Pubmed	HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.	PSMC2 PSMD4 PSMD13 PSME1	6.41e-06	39	107	4	14528301
Pubmed	The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.	PSMC2 PSMD4 PSMD13 PSME1	7.11e-06	40	107	4	14528300
Pubmed	Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.	PSMC2 PSMD4 PSMD13 PSME1	7.11e-06	40	107	4	12167863
Pubmed	The RTP site shared by the HIV-1 Tat protein and the 11S regulator subunit alpha is crucial for their effects on proteasome function including antigen processing.	PSMC2 PSMD4 PSMD13 PSME1	7.11e-06	40	107	4	12419264
Pubmed	HIV-1 tat inhibits the 20 S proteasome and its 11 S regulator-mediated activation.	PSMC2 PSMD4 PSMD13 PSME1	7.85e-06	41	107	4	9079628
Pubmed	Human immunodeficiency virus-1 Tat protein interacts with distinct proteasomal alpha and beta subunits.	PSMC2 PSMD4 PSMD13 PSME1	7.85e-06	41	107	4	14550573
Pubmed	Uncovering a new role for peroxidase enzymes as drivers of angiogenesis.	MPO EPX	9.38e-06	2	107	2	26386352
Pubmed	Inflammatory peroxidases promote breast cancer progression in mice via regulation of the tumour microenvironment.	MPO EPX	9.38e-06	2	107	2	28260049
Pubmed	Taf1 knockout is lethal in embryonic male mice and heterozygous females show weight and movement disorders.	TAF1 TAF1L	9.38e-06	2	107	2	38804708
Pubmed	Characterization of LILRB3 and LILRA6 allelic variants in the Japanese population.	LILRB3 LILRA6	9.38e-06	2	107	2	33526815
Pubmed	Sustained expression of a neuron-specific isoform of the Taf1 gene in development stages and aging in mice.	TAF1 TAF1L	9.38e-06	2	107	2	22842574
Pubmed	Frameshift Mutations in the Mononucleotide Repeats of TAF1 and TAF1L Genes in Gastric and Colorectal Cancers with Regional Heterogeneity.	TAF1 TAF1L	9.38e-06	2	107	2	27571988
Pubmed	Striatal Cholinergic Dysregulation after Neonatal Decrease in X-Linked Dystonia Parkinsonism-Related TAF1 Isoforms.	TAF1 TAF1L	9.38e-06	2	107	2	34403156
Pubmed	Diagnostic utility of NCOA2 fluorescence in situ hybridization and Stat6 immunohistochemistry staining for soft tissue angiofibroma and morphologically similar fibrovascular tumors.	NCOA2 STAT6	9.38e-06	2	107	2	24856853
Pubmed	Expression of p15INK⁴b and p57KIP² and relationship with clinicopathological features and prognosis in patients with vulvar squamous cell carcinoma.	CDKN1C CDKN2B	9.38e-06	2	107	2	23580324
Pubmed	Hereditary eosinophil peroxidase deficiency: immunochemical and spectroscopic studies and evidence for a compound heterozygosity of the defect.	MPO EPX	9.38e-06	2	107	2	7809065
Pubmed	Distinct frequency patterns of LILRB3 and LILRA6 allelic variants in Europeans.	LILRB3 LILRA6	9.38e-06	2	107	2	36449053
Pubmed	Peroxidase enzymes inhibit osteoclast differentiation and bone resorption.	MPO EPX	9.38e-06	2	107	2	27836774
Pubmed	Allogeneic disparities in immunoglobulin-like transcript 5 induce potent antibody responses in hematopoietic stem cell transplant recipients.	LILRB3 LILRA6	9.38e-06	2	107	2	19617579
Pubmed	TAFII250, Egr-1, and D-type cyclin expression in mice and neonatal rat cardiomyocytes treated with doxorubicin.	TAF1 TAF1L	9.38e-06	2	107	2	10070062
Pubmed	Sequence and expression of a novel human T-cell receptor beta-chain variable gene segment subfamily.	TRBV11-3 TRBV11-1	9.38e-06	2	107	2	2272661
Pubmed	Diversity of the human LILRB3/A6 locus encoding a myeloid inhibitory and activating receptor pair.	LILRB3 LILRA6	9.38e-06	2	107	2	24096970
Pubmed	Leukocyte immunoglobulin-like receptors maintain unique antigen-presenting properties of circulating myeloid dendritic cells in HIV-1-infected elite controllers.	LILRB3 LILRB1	9.38e-06	2	107	2	20631139
Pubmed	Promoter variant -204A > C of the cholesterol 7α-hydroxylase gene: association with response to plant sterols in humans and increased transcriptional activity in transfected HepG2 cells.	CYP7A1 CYP17A1	9.38e-06	2	107	2	20884100
Pubmed	Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.	PSMC2 PSMD4 PSMD13 PSME1	9.53e-06	43	107	4	14564014
Pubmed	Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.	PSMC2 PSMD4 PSMD13 PSME1	1.05e-05	44	107	4	12859895
Pubmed	Mass spectrometric characterization of the affinity-purified human 26S proteasome complex.	PSMC2 PSMD4 PSMD13 PSME1	1.25e-05	46	107	4	17323924
Pubmed	The proteasome-interacting Ecm29 protein disassembles the 26S proteasome in response to oxidative stress.	PSMC2 PSMD4 PSMD13 PSME1	1.25e-05	46	107	4	28821611
Pubmed	A human MAP kinase interactome.	ANK3 SPTBN2 LAMB2 PSMD4 ZGPAT CLTC TAF1 HERC2 ZNF839	2.02e-05	486	107	9	20936779
Pubmed	Branched ubiquitin chain binding and deubiquitination by UCH37 facilitate proteasome clearance of stress-induced inclusions.	PSMC2 PSMD4 PSMD13 PSME1	2.38e-05	54	107	4	34761751
Pubmed	Prophase destruction of Emi1 by the SCF(betaTrCP/Slimb) ubiquitin ligase activates the anaphase promoting complex to allow progression beyond prometaphase.	PSMC2 PSMD4 PSMD13 PSME1	2.56e-05	55	107	4	12791267
Pubmed	AKIRIN2 controls the nuclear import of proteasomes in vertebrates.	PSMC2 PSMD4 PSMD13 PSME1	2.56e-05	55	107	4	34711951
Pubmed	In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine.	MPO LAMB2 CPE EPX MYOF HMCN1 BAIAP2L1 TLN1 CLTC RAB2A ENO3 SERPINA5 SDCBP	2.57e-05	1070	107	13	23533145
Pubmed	Autoregulation of the 26S proteasome by in situ ubiquitination.	PSMC2 PSMD4 HERC2	2.65e-05	19	107	3	24743594
Pubmed	Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia.	CDKN1C CDKN2B	2.81e-05	3	107	2	19109226
Pubmed	The potential for repositioning antithyroid agents as antiasthma drugs.	MPO EPX	2.81e-05	3	107	2	27444178
Pubmed	The Mediterranean diet reduces the genetic risk of chromosome 9p21 for myocardial infarction in an Asian population community cohort.	CDKN2B MIA3	2.81e-05	3	107	2	31804579
Pubmed	Peroxidasin and eosinophil peroxidase, but not myeloperoxidase, contribute to renal fibrosis in the murine unilateral ureteral obstruction model.	MPO EPX	2.81e-05	3	107	2	30565999
Pubmed	The evolutionary conservation of the mammalian peroxidase genes.	MPO EPX	2.81e-05	3	107	2	12584448
Pubmed	IL-18 with IL-2 protects against Strongyloides venezuelensis infection by activating mucosal mast cell-dependent type 2 innate immunity.	IL18 STAT6	2.81e-05	3	107	2	16129701
Pubmed	A PH domain within OCRL bridges clathrin-mediated membrane trafficking to phosphoinositide metabolism.	INPP5B CLTC	2.81e-05	3	107	2	19536138
Pubmed	Structural determinants for the binding of ubiquitin-like domains to the proteasome.	PSMC2 PSMD4	2.81e-05	3	107	2	12970176
Pubmed	Regulated expression of TAF1 in 1-cell mouse embryos.	TAF1 TAF1L	2.81e-05	3	107	2	16822332
Pubmed	Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia.	CDKN1C CDKN2B	2.81e-05	3	107	2	15978938
Pubmed	Thiocyanate modulates the catalytic activity of mammalian peroxidases.	MPO EPX	2.81e-05	3	107	2	15894800
Pubmed	TAFII55 binding to TAFII250 inhibits its acetyltransferase activity.	TAF1 TAF1L	2.81e-05	3	107	2	11592977
Pubmed	Structure of the NCoA-1/SRC-1 PAS-B domain bound to the LXXLL motif of the STAT6 transactivation domain.	NCOA2 STAT6	2.81e-05	3	107	2	14757047
Pubmed	The eosinophil peroxidase gene forms a cluster with the genes for myeloperoxidase and lactoperoxidase on human chromosome 17.	MPO EPX	2.81e-05	3	107	2	10828600
Pubmed	Functional substitution for TAF(II)250 by a retroposed homolog that is expressed in human spermatogenesis.	TAF1 TAF1L	2.81e-05	3	107	2	12217962
Pubmed	TAF7: a possible transcription initiation check-point regulator.	TAF1 TAF1L	2.81e-05	3	107	2	16407123
Pubmed	Mammalian Cdh1/Fzr mediates its own degradation.	PSMC2 PSMD4 PSMD13 PSME1	3.38e-05	59	107	4	15029244
Pubmed	Affinity purification strategy to capture human endogenous proteasome complexes diversity and to identify proteasome-interacting proteins.	PSMC2 PSMD4 PSMD13 PSME1	4.39e-05	63	107	4	19193609
Pubmed	A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease.	ANK3 CYP17A1 CPEB3 ITGA8 CPN1 PAPSS2 MYOF CHRDL1	4.47e-05	415	107	8	16385451
Pubmed	Alternative exon skipping biases substrate preference of the deubiquitylase USP15 for mysterin/RNF213, the moyamoya disease susceptibility factor.	PSMC2 PSMD4 PSMD13 USP32	4.96e-05	65	107	4	28276505
Pubmed	Phosphatase UBLCP1 controls proteasome assembly.	PSMC2 PSMD4 PSMD13	5.47e-05	24	107	3	28539385
Pubmed	Anaphase-promoting complex/cyclosome-dependent proteolysis of human cyclin A starts at the beginning of mitosis and is not subject to the spindle assembly checkpoint.	PSMC2 PSMD4 PSMD13 PSME1	5.59e-05	67	107	4	11285280
Pubmed	Degradation of some polyubiquitinated proteins requires an intrinsic proteasomal binding element in the substrates.	PSMC2 PSMD4	5.60e-05	4	107	2	20007692
Pubmed	A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells.	LILRB3 LILRB1	5.60e-05	4	107	2	9382880
Pubmed	IL-18 contributes to the spontaneous development of atopic dermatitis-like inflammatory skin lesion independently of IgE/stat6 under specific pathogen-free conditions.	IL18 STAT6	5.60e-05	4	107	2	12151598
Pubmed	Interleukin-13 induces mucin 5AC production involving STAT6/SPDEF in human airway epithelial cells.	STAT6 MUC5AC	5.60e-05	4	107	2	21275604
Pubmed	The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma.	CDKN1C CDKN2B	5.60e-05	4	107	2	17885492
Pubmed	P160/SRC/NCoA coactivators form complexes via specific interaction of their PAS-B domain with the CID/AD1 domain.	NCOA2 STAT6	5.60e-05	4	107	2	18267973
Pubmed	Targeted inhibition of p57 and p15 blocks transforming growth factor beta-inhibited proliferation of primary cultured human limbal epithelial cells.	CDKN1C CDKN2B	5.60e-05	4	107	2	16943770
Pubmed	Mfge8 promotes obesity by mediating the uptake of dietary fats and serum fatty acids.	MFGE8 SLC27A1	5.60e-05	4	107	2	24441829
Pubmed	E-cadherin interactome complexity and robustness resolved by quantitative proteomics.	ISYNA1 ANK3 ARHGAP23 SPTBN2 BAIAP2L1 TLN1 PPP1R18 PCDH1 SDCBP	6.47e-05	565	107	9	25468996
Pubmed	Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization.	PSMC2 PSMD4 PSMD13 PSME1	7.02e-05	71	107	4	23503661
Pubmed	Large-scale proteomics and phosphoproteomics of urinary exosomes.	MPO MYOF MFGE8 BAIAP2L1 MYH14 TLN1 CLTC ALDH3B1 RAB2A SERPINA5 SDCBP CRTC2	7.03e-05	1016	107	12	19056867
Pubmed	A novel proteasome interacting protein recruits the deubiquitinating enzyme UCH37 to 26S proteasomes.	PSMC2 PSMD4 PSMD13	7.85e-05	27	107	3	16990800
Pubmed	Iron metabolism mutant hbd mice have a deletion in Sec15l1, which has homology to a yeast gene for vesicle docking.	CPEB3 MYOF	9.32e-05	5	107	2	16289749
Pubmed	Fluctuations of Spleen Cytokine and Blood Lactate, Importance of Cellular Immunity in Host Defense Against Blood Stage Malaria Plasmodium yoelii.	PSME1 MFGE8	9.32e-05	5	107	2	31608052
Pubmed	Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells.	CDKN1C CDKN2B	9.32e-05	5	107	2	26362858
Cytoband	19q13.4	ZNF135 LILRB3 LILRA6 LILRB1	3.66e-05	79	107	4	19q13.4
Cytoband	Ensembl 112 genes in cytogenetic band chr8q12	CYP7A1 CHD7 RAB2A SDCBP	6.65e-05	92	107	4	chr8q12
Cytoband	Ensembl 112 genes in cytogenetic band chr10q23	CPEB3 LIPN PAPSS2 MYOF PIPSL	9.83e-05	195	107	5	chr10q23
Cytoband	17q23.1	MPO EPX	6.32e-04	16	107	2	17q23.1
Cytoband	Ensembl 112 genes in cytogenetic band chr17q22	MPO EPX MTMR4	1.17e-03	88	107	3	chr17q22
Cytoband	11q13	SPTBN2 NRXN2 ALDH3B1	2.70e-03	118	107	3	11q13
Cytoband	11p15.5	CDKN1C PSMD13 MUC5AC	2.70e-03	118	107	3	11p15.5
Cytoband	10q24	PAPSS2 MYOF	3.05e-03	35	107	2	10q24
GeneFamily	Proteasome	PSMC2 PSMD4 PSMD13 PSME1	3.14e-05	43	76	4	690
GeneFamily	CD molecules\|Inhibitory leukocyte immunoglobulin like receptors	LILRB3 LILRB1	1.73e-04	5	76	2	1182
Coexpression	THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_RESPONDERS_28DY_DN	CDKN1C LILRB3 IL18 HK3 IFFO1 LILRA6 LILRB1 STAT6 CLIP4 MYOF USP32 NSUN5P2 PPP1R18 ZNF839 ENO3 CYTH4	7.21e-07	905	106	16	M40865
Coexpression	GSE34156_UNTREATED_VS_6H_TLR1_TLR2_LIGAND_TREATED_MONOCYTE_UP	LILRB3 RPS6KA4 LILRA6 LILRB1 MYOF WDFY3 ALDH3B1	1.58e-05	197	106	7	M8672
Coexpression	GSE34156_TLR1_TLR2_LIGAND_VS_NOD2_AND_TLR1_TLR2_LIGAND_24H_TREATED_MONOCYTE_UP	LILRB3 DUSP3 LILRA6 MYOF TLN1 WDFY3 RAB2A	1.58e-05	197	106	7	M8676
Coexpression	GSE339_CD4POS_VS_CD4CD8DN_DC_DN	CDKN2B ABCA4 SPTBN2 GPATCH2 ITGA8 CPE GRSF1	1.75e-05	200	106	7	M5116
Coexpression	GSE10325_LUPUS_BCELL_VS_LUPUS_MYELOID_DN	LILRB3 HK3 LILRB1 MYOF WDFY3 ALDH3B1 SDCBP	1.75e-05	200	106	7	M3091
Coexpression	GSE10325_LUPUS_CD4_TCELL_VS_LUPUS_MYELOID_DN	LILRB3 HK3 DUSP3 LILRB1 MYOF ALDH3B1 SDCBP	1.75e-05	200	106	7	M3088
Coexpression	GOZGIT_ESR1_TARGETS_DN	CDKN2B LILRB3 ANK3 SPTBN2 PCDHB10 GPATCH2 CPE ZNF229 PAPSS2 ZGPAT HMCN1 NUAK1 SERPINA5	1.76e-05	786	106	13	M10961
Coexpression	VERHAAK_GLIOBLASTOMA_MESENCHYMAL	LILRB3 HK3 ICAM3 STAT6 MYOF ALDH3B1 CYTH4	2.86e-05	216	106	7	M2122
Coexpression	THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_RESPONDERS_7DY_DN	LILRB3 IL18 IFFO1 LILRA6 STAT6 CLIP4 USP32 PPP1R18 ZNF839 ENO3 CYTH4	5.29e-05	634	106	11	M40866
Coexpression	CAHOY_ASTROCYTIC	AGPAT4 PAPSS2 MFGE8 SLC27A1 CHRDL1	5.46e-05	100	106	5	M2806
Coexpression	GAUTAM_EYE_CORNEA_MELANOCYTES	ISYNA1 IFFO1 PSMC2 PSMD13 MFGE8 SLC27A1 TLN1	9.44e-05	261	106	7	M43615
Coexpression	LEF1_UP.V1_DN	IL18 ANK3 CPE PAPSS2 MFGE8 MOCOS	1.15e-04	187	106	6	M2903
Coexpression	ERBB2_UP.V1_UP	MIA3 SPTBN2 LAMB2 PAPSS2 PCDH1 SDCBP	1.25e-04	190	106	6	M2636
Coexpression	HOXA9_DN.V1_UP	MPO SCHIP1 IFFO1 ICAM3 ZCCHC2 MYOF	1.33e-04	192	106	6	M2850
Coexpression	GSE3982_EOSINOPHIL_VS_TH2_UP	HK3 INPP5B CPEB3 CPN1 PPM1F MUC5AC	1.44e-04	195	106	6	M5424
Coexpression	GSE1460_CD4_THYMOCYTE_VS_NAIVE_CD4_TCELL_CORD_BLOOD_DN	INPP5B LAMB2 PKN1 WDFY3 HERC2 TARBP1	1.53e-04	197	106	6	M3472
Coexpression	GSE11057_PBMC_VS_MEM_CD4_TCELL_UP	LILRB3 IL18 HK3 LILRA6 LILRB1 MYOF	1.53e-04	197	106	6	M3120
Coexpression	GSE10273_HIGH_VS_LOW_IL7_TREATED_IRF4_8_NULL_PRE_BCELL_DN	NCOA2 MIA3 RPS6KA4 CHD7 PKN1 HERC2	1.61e-04	199	106	6	M316
Coexpression	GSE14308_TH1_VS_TH17_DN	MIA3 INPP5B PSMD4 SH3YL1 NUAK1 PPM1F	1.66e-04	200	106	6	M3374
Coexpression	GSE29618_MONOCYTE_VS_MDC_UP	MPO LILRB3 IFFO1 LILRA6 LILRB1 SDCBP	1.66e-04	200	106	6	M4948
Coexpression	GSE22886_NAIVE_TCELL_VS_MONOCYTE_DN	LILRB3 HK3 DUSP3 LILRA6 LILRB1 SDCBP	1.66e-04	200	106	6	M4480
ToppCell	COVID-19_Moderate-Non-classical_Monocyte\|COVID-19_Moderate / disease group, cell group and cell class	CDKN1C LILRB3 HK3 LIPN LILRB1 CLIP4 MYOF PPM1F ALDH3B1	1.17e-09	196	107	9	256c557fa11414c9d2cbb1fcff33f482ee1c78ac
ToppCell	COVID-19_Severe-Non-classical_Monocyte\|World / disease group, cell group and cell class	CDKN1C LILRB3 HK3 PAPSS2 LILRB1 CLIP4 MYOF PPM1F ALDH3B1	1.22e-09	197	107	9	60fee75b12451206bb2c07b61651a73c59ec6ade
ToppCell	COVID-19_Moderate-Non-classical_Monocyte\|World / disease group, cell group and cell class	CDKN1C LILRB3 HK3 LIPN LILRB1 CLIP4 MYOF PPM1F ALDH3B1	1.28e-09	198	107	9	8449934e20bb2a34079fb642cae0d4647b9efe51
ToppCell	severe_COVID-19-Non-classical_Monocyte\|World / disease group, cell group and cell class (v2)	CDKN1C LILRB3 HK3 LIPN PAPSS2 LILRB1 PPM1F ALDH3B1	2.44e-08	195	107	8	72928a1d987a3a5361c666f3972292aefec5f548
ToppCell	proximal-Hematologic-Nonclassical_Monocyte-3\|proximal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	CDKN1C LILRB3 HK3 ICAM3 LILRA6 LIPN LILRB1 CYTH4	2.53e-08	196	107	8	7e136975e5943d42d51d8cc91c912547ef79cf4d
ToppCell	proximal-3-Hematologic-Nonclassical_Monocyte\|3 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	CDKN1C LILRB3 HK3 ICAM3 LILRA6 LIPN LILRB1 CYTH4	2.53e-08	196	107	8	e426d02c6bcff2358a45e627cc86389070a4af25
ToppCell	COVID-19_Severe-Non-classical_Monocyte\|COVID-19_Severe / disease group, cell group and cell class	CDKN1C HK3 PAPSS2 LILRB1 CLIP4 MYOF PPM1F ALDH3B1	2.53e-08	196	107	8	af9e8f5ef9d03862f707e105857309b55595b1b9
ToppCell	proximal-Hematologic-Nonclassical_Monocyte\|proximal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	CDKN1C LILRB3 HK3 ICAM3 LILRA6 LIPN LILRB1 CYTH4	2.53e-08	196	107	8	439d695526714772971fd1a4a92b8b6a84eee1a4
ToppCell	10x5'-lymph-node_spleen-Myeloid_Monocytic-Nonclassical_monocytes\|lymph-node_spleen / Manually curated celltypes from each tissue	CDKN1C HK3 LILRA6 LIPN PAPSS2 LILRB1 MYOF ALDH3B1	2.64e-08	197	107	8	67f19dd30adb03300f04219d0295bc1c1788f626
ToppCell	Tracheal-10x5prime-Immune_Myeloid-Monocytic-Monocyte_CD16\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	CDKN1C LILRB3 HK3 LILRA6 LIPN LILRB1 ENO3 CYTH4	2.96e-08	200	107	8	5ea3e74687893b8ca6cb915f0f14a14d4692775c
ToppCell	Bronchial-10x5prime-Immune_Myeloid-Monocytic-Monocyte_CD16\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	CDKN1C LILRB3 HK3 LILRA6 LIPN PAPSS2 LILRB1 CYTH4	2.96e-08	200	107	8	d39bf03817b76c9dfcbcd868341b51bb8601ea9b
ToppCell	10x5'-lymph-node_spleen-Hematopoietic_progenitors-Progenitor\|lymph-node_spleen / Manually curated celltypes from each tissue	MPO SCHIP1 NPTX2 TRIM71 RAB44 MED12L CHRDL1	1.50e-07	165	107	7	7b992843bd8ef92a7a76b1d681fa84efde6f5bdd
ToppCell	3'_v3-GI_small-bowel-Myeloid_Monocytic-Nonclassical_monocytes\|GI_small-bowel / Manually curated celltypes from each tissue	HK3 LILRA6 LIPN PAPSS2 LILRB1 MYOF ALDH3B1	3.52e-07	187	107	7	c20689022569640ebc4a878e3fe146b86fe9b386
ToppCell	Monocytes-Inflammatory_CD16+_macrophages\|World / Immune cells in Kidney/Urine in Lupus Nephritis	CDKN1C LILRB3 HK3 PAPSS2 LILRB1 MYOF ALDH3B1	4.20e-07	192	107	7	4be5c2c946337cd3e710137726358adca563f146
ToppCell	healthy_donor-Myeloid-Monocytic-CD16+_Monocyte\|healthy_donor / Disease condition, Lineage, Cell class and subclass	CDKN1C HK3 PAPSS2 LILRB1 MYOF PPM1F ALDH3B1	4.50e-07	194	107	7	ecf746ef1c5c4d6d9ca06a6d3e3778670b5700c2
ToppCell	PBMC_fresh-frozen-Severe-critical_convalescent_d14-21-Myeloid-Monocytic-Nonclassical_Monocyte-Mono_c4-CD14-CD16\|Severe-critical_convalescent_d14-21 / Compartment, severity and other cell annotations on 10x 3' data (130k)	CDKN1C LILRB3 HK3 LILRA6 LILRB1 MYOF WDFY3	4.66e-07	195	107	7	3a30479857fc2805df92655c9599389559b1995d
ToppCell	10x5'v1-week_12-13-Myeloid_neutrophil-granulo-neutrophil\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	MPO LILRB3 HK3 ICAM3 LILRB1 PKN1 ALDH3B1	4.66e-07	195	107	7	fb3dc2c8fd125f23d0c3aa211520778aac8d6dda
ToppCell	10x5'-blood-Myeloid_Monocytic-Nonclassical_monocytes\|blood / Manually curated celltypes from each tissue	CDKN1C HK3 PAPSS2 LILRB1 MYOF PPM1F ALDH3B1	4.66e-07	195	107	7	88d65c7c3a28922c125bd9f7c403a55d7d4d83a9
ToppCell	PBMC-Mild-Myeloid-Non-classical_Monocyte\|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)	CDKN1C LILRB3 HK3 LILRB1 MYOF PPM1F ALDH3B1	5.00e-07	197	107	7	083fec147040ee0bebac2815fb89355cf3a7ffa5
ToppCell	PBMC-Mild-Myeloid-Non-classical_Monocyte-Non-classical_Monocyte\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CDKN1C LILRB3 HK3 LILRB1 MYOF PPM1F ALDH3B1	5.00e-07	197	107	7	f0e6745b0fd734ea17e7a2a883e48017e8d3102d
ToppCell	PBMC-Mild-Myeloid-Non-classical_Monocyte-Non-classical_Monocyte\|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)	CDKN1C LILRB3 HK3 LILRB1 MYOF PPM1F ALDH3B1	5.00e-07	197	107	7	b82142cf8057a55dfa884248b752173661edffd1
ToppCell	PBMC-Mild-Myeloid-Non-classical_Monocyte-Non-classical_Monocyte-\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CDKN1C LILRB3 HK3 LILRB1 MYOF PPM1F ALDH3B1	5.00e-07	197	107	7	96d56bce69de7192c7a6b43371b56f4acdcc7733
ToppCell	PBMC-Mild-Myeloid-Non-classical_Monocyte-Non-classical_Monocyte-\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	CDKN1C LILRB3 HK3 LILRB1 MYOF PPM1F ALDH3B1	5.00e-07	197	107	7	70faaea9c143337a52c8f660ebb063aa92327357
ToppCell	PBMC-Mild-Myeloid-Non-classical_Monocyte\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CDKN1C LILRB3 HK3 LILRB1 MYOF PPM1F ALDH3B1	5.00e-07	197	107	7	422074930fce25a6ad15ba41e391c65787e7878e
ToppCell	COVID-19_Mild-Myeloid-Non-classical_Monocyte\|COVID-19_Mild / Disease group, lineage and cell class	CDKN1C LILRB3 HK3 LILRB1 MYOF PPM1F ALDH3B1	5.00e-07	197	107	7	9c943d18f8e6cb0ce9f2158d50796fafae5c81d4
ToppCell	Healthy/Control-Non-classical_Monocyte\|Healthy/Control / Disease group and Cell class	CDKN1C LILRB3 HK3 LILRB1 MYOF PPM1F ALDH3B1	5.17e-07	198	107	7	0badaf1fa5328d06291c3624d0f63196ffc81527
ToppCell	mLN-(4)_Monocyte\|mLN / shred on region, Cell_type, and subtype	LILRB3 HK3 LILRA6 LAMB2 LIPN PAPSS2 ALDH3B1	5.35e-07	199	107	7	6795ff31f92580195c9db776951f99d647484d24
ToppCell	mLN-Monocyte\|mLN / Region, Cell class and subclass	LILRB3 HK3 LILRA6 LAMB2 LIPN PAPSS2 ALDH3B1	5.35e-07	199	107	7	241f790cd5d8a9b2451333deecc826a673bae70a
ToppCell	mLN-Monocyte-Monocyte\|mLN / Region, Cell class and subclass	LILRB3 HK3 LILRA6 LAMB2 LIPN PAPSS2 ALDH3B1	5.35e-07	199	107	7	dcee372774c169a3048bdaed3734b3215bf8ffad
ToppCell	mLN-(4)_Monocyte-(40)_Monocyte\|mLN / shred on region, Cell_type, and subtype	LILRB3 HK3 LILRA6 LAMB2 LIPN PAPSS2 ALDH3B1	5.35e-07	199	107	7	bcbb1eee8d79bf670dbe113094c3a292b135ce2f
ToppCell	Parenchymal-10x5prime-Immune_Myeloid-Monocytic-Monocyte_CD16\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	CDKN1C LILRB3 HK3 LILRA6 LIPN LILRB1 CYTH4	5.53e-07	200	107	7	83d9aa5b46ae7a71a258b2e44b3251f95bc9a1b7
ToppCell	COVID-19-COVID-19_Mild-Myeloid-CD16+_Monocyte\|COVID-19_Mild / Disease, condition lineage and cell class	CDKN1C LILRB3 HK3 LILRB1 MYOF PPM1F ALDH3B1	5.53e-07	200	107	7	5c0eb14bdf1bfeaf93f6c3d521529bd5a4de50ce
ToppCell	Bronchial-NucSeq-Immune_Myeloid-Monocytic-Monocyte_CD16\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	LILRB3 HK3 LILRA6 LIPN LILRB1 PPM1F CYTH4	5.53e-07	200	107	7	fc061de0db2e8b5ca47f5e2a1e861018e7f1b582
ToppCell	(61)_LYVE1_Macrophage\|World / shred on Cell_type and subtype	LILRB3 HK3 LILRA6 PAPSS2 MYOF WDFY3 ALDH3B1	6.74e-07	206	107	7	711e961a9a03bfd2f0958bd14f25f7f207a2f2b5
ToppCell	LPS_only-Myeloid-Monocytes,_Macrophages-Erythroid\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	IL18 HK3 AGPAT4 LIPN ALDH3B1 POU2F3	1.09e-06	139	107	6	d96e5c17582f1576fa09d6bad35c418b6248448c
ToppCell	5'-Adult-Appendix-Hematopoietic-Myeloid-Monocytes\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	LILRB3 HK3 LILRA6 LIPN LILRB1 RAB44	3.51e-06	170	107	6	1c3c03821c90d41de92fef3278f71093a7fd709c
ToppCell	LPS-IL1RA-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CDKN2B ABCA4 MYOF BAIAP2L1 MYH14 MOCOS	4.72e-06	179	107	6	04ce3673e46606f63d9c87bcba3a64c96817d812
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_1-AT1\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CDKN2B PON3 SH3YL1 BAIAP2L1 MYH14 ALDH3B1	5.36e-06	183	107	6	274483009b309289e4cb84beedf6806430db6ff6
ToppCell	PND07-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2-AT2_mature\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ANK3 PON3 CLIP4 BAIAP2L1 MYH14 CLTC	5.53e-06	184	107	6	49705c8fec565b16216bdf48e83e27521f52d99a
ToppCell	COVID-19_Moderate-HSPC\|World / disease group, cell group and cell class	SCHIP1 NPTX2 ISYNA1 SPTBN2 MED12L CHRDL1	5.53e-06	184	107	6	ccc93babe1fcdeb66b78e1d8414357877a7c45bd
ToppCell	PND01-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2-AT2_mature\|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ANK3 PON3 PSME1 CLIP4 BAIAP2L1 CLTC	5.71e-06	185	107	6	fd51fef8c69e34c72017d8371ab0a0d7be5701f2
ToppCell	PND01-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2\|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ANK3 PON3 PSME1 CLIP4 BAIAP2L1 CLTC	5.71e-06	185	107	6	bea26e369ae91006052b973cd89b4c49afa9e553
ToppCell	PND07-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ANK3 PON3 CLIP4 BAIAP2L1 MYH14 CLTC	5.71e-06	185	107	6	2adb32096aa3473f8d417e5ce9e65264beca9b52
ToppCell	PND01-03-samps-Epithelial\|PND01-03-samps / Age Group, Lineage, Cell class and subclass	CDKN2B ANK3 PON3 CLIP4 BAIAP2L1 MYH14	5.71e-06	185	107	6	2b854df79cfe2cb4d2f9c2938a066e0aa3649325
ToppCell	3'_v3-lymph-node_spleen-Myeloid_Monocytic-Nonclassical_monocytes\|lymph-node_spleen / Manually curated celltypes from each tissue	CDKN1C LIPN PAPSS2 LILRB1 MYOF PPM1F	5.89e-06	186	107	6	d7da5edb2ee36f96cdd7e27eb9afcc1cbfd52bb6
ToppCell	Healthy-HSPC\|World / disease group, cell group and cell class	SCHIP1 NPTX2 ISYNA1 IL18 SPTBN2 MED12L	6.07e-06	187	107	6	8cd9e5499e5c2b2321ecbcf780df37fe0f165ac9
ToppCell	PND01-03-samps-Epithelial-Alveolar_epithelial\|PND01-03-samps / Age Group, Lineage, Cell class and subclass	CDKN2B ANK3 PON3 CLIP4 BAIAP2L1 MYH14	6.07e-06	187	107	6	23fe3cdd6cc9b067086a8392d104186d300298ea
ToppCell	wk_08-11-Hematologic-Myeloid-Promonocyte-like\|wk_08-11 / Celltypes from embryonic and fetal-stage human lung	MPO LILRB3 IL18 HK3 ICAM3 RAB44	6.26e-06	188	107	6	2ae945d96a011f246d04a42bcd6ef443232b03f4
ToppCell	Monocytes-SSc-ILD_02\|World / lung cells shred on cell class, cell subclass, sample id	CDKN1C LILRB3 ICAM3 LIPN PSME1 LILRB1	6.45e-06	189	107	6	2164adbe1b0e8e4d39644546b7dfb19e9ea4f7b9
ToppCell	Control-Myeloid-Monocytes\|Control / group, cell type (main and fine annotations)	LILRB3 HK3 LIPN LILRB1 PPM1F CYTH4	6.45e-06	189	107	6	3335d16bd0ffa0c1ddd06d7da645299148130c3f
ToppCell	IPF-Myeloid-ncMonocyte\|Myeloid / Disease state, Lineage and Cell class	NCOA2 CDKN1C LIPN PAPSS2 LILRB1 PPM1F	6.45e-06	189	107	6	5c22d2d935f7bb270260b8bc6be67b565ec401bf
ToppCell	PND03-Epithelial\|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CDKN2B ANK3 CLIP4 BAIAP2L1 MYH14 CLTC	7.06e-06	192	107	6	d8c23693f690d4d568585537bbfedda05d505b3d
ToppCell	5'-Adult-Distal_Rectal-Mesenchymal-Pericytes\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CDKN1C SCHIP1 ISYNA1 MFGE8 TLN1 ASTN1	7.27e-06	193	107	6	7631bf3362b4fa061ffeab4879ab12c4708dc4c0
ToppCell	3'-GW_trimst-1-SmallIntestine-Hematopoietic-Myeloid-MPO+_mono-neutrophil\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	MPO LILRB3 HK3 ICAM3 LIPN RAB44	7.27e-06	193	107	6	35998200890fef12e7f4a3dc65eca1c30d19fa93
ToppCell	5'-Adult-Distal_Rectal-Mesenchymal-Pericytes-Contractile_pericyte_(PLN+)\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CDKN1C SCHIP1 ISYNA1 MFGE8 TLN1 ASTN1	7.27e-06	193	107	6	8d15c63f2ae48d0a00d7ef5fdafa917ab8ad0571
ToppCell	5'-GW_trimst-2-SmallIntestine-Hematopoietic-Myeloid-Monocytes\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	LILRB3 HK3 ICAM3 LILRA6 LIPN LILRB1	7.27e-06	193	107	6	c0509798ce06da0ec725c0c7b5cc195455f2c29f
ToppCell	10x5'v1-week_17-19-Myeloid_neutrophil-granulo-neutrophil-neutrophil\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	LILRB3 HK3 ICAM3 LILRA6 LILRB1 SDCBP	7.49e-06	194	107	6	e2d0dfb92356fa7ad7008aa8ac4198e2ac5d2495
ToppCell	COVID-19_Severe-Non-classical_Monocyte-\|COVID-19_Severe / Disease condition and Cell class	CDKN1C PAPSS2 LILRB1 CLIP4 MYOF PKN1	7.49e-06	194	107	6	d70b9039fd2fef3e4be086513b94fb7e9bc1f670
ToppCell	3'-Broncho-tracheal-Immune_Myeloid-Myeloid_monocytic-non-classical_monocyte-Non-classical_monocytes-Non-classical_monocytes_L.1.2.2.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CDKN1C ICAM3 LIPN PAPSS2 LILRB1 PPM1F	7.49e-06	194	107	6	16c6fcbd36d473b883fb5361caca86eb134767ab
ToppCell	COVID-19_Severe-Non-classical_Monocyte\|COVID-19_Severe / Disease condition and Cell class	CDKN1C PAPSS2 LILRB1 CLIP4 MYOF PKN1	7.49e-06	194	107	6	5151546812678ae85cb22224084d27b29e3c4724
ToppCell	cellseq-Immune-Immune_Myeloid-pMON-pMON\|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	LILRB3 HK3 ICAM3 LIPN LILRB1 CYTH4	7.71e-06	195	107	6	2cb435dae2691e1250e26e59f9b8fb652a0c383e
ToppCell	cellseq-Immune-Immune_Myeloid-pMON\|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	LILRB3 HK3 ICAM3 LIPN LILRB1 CYTH4	7.71e-06	195	107	6	217908cb53016a6cb51f1bc3fc752c8df650df71
ToppCell	human_hepatoblastoma-Inflammatory_Monocytes\|human_hepatoblastoma / Sample and Cell Type and Tumor Cluster (all cells)	LILRB3 IL18 PAPSS2 LILRB1 CLIP4 CYTH4	7.71e-06	195	107	6	ba7f85e5307d96ac5ad7c952f8d094db9ca1790c
ToppCell	mild-Myeloid-CD16_Monocytes\|mild / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs	CDKN1C HK3 PAPSS2 LILRB1 MYOF ALDH3B1	7.71e-06	195	107	6	e963d33b50d43e38cada738e41343b64e3d08b79
ToppCell	severe_COVID-19-Non-classical_Monocyte\|severe_COVID-19 / disease group, cell group and cell class (v2)	CDKN1C PAPSS2 LILRB1 MYOF PPM1F ALDH3B1	7.94e-06	196	107	6	34c1c74cad5e23196e86cfd6f19c836fe57b2264
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-Mono-Mono_hypoxia-C\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	MPO HK3 LILRA6 LIPN RAB44 SDCBP	7.94e-06	196	107	6	9ae9cf69079b8a786e775c3db5cd4c593513f698
ToppCell	10x5'v1-week_17-19-Myeloid_neutrophil-granulo-neutrophil\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	LILRB3 HK3 ICAM3 LILRA6 LILRB1 SDCBP	7.94e-06	196	107	6	ad193b231ff2f7c72590fab79919c179d5d2f327
ToppCell	remission-Non-classical_Monocyte\|remission / disease stage, cell group and cell class	CDKN1C LILRB3 HK3 LILRB1 MYOF ALDH3B1	7.94e-06	196	107	6	049d995986c20ce066bd64fcc2d2f1c2f8899883
ToppCell	wk_15-18-Hematologic-Myeloid-Neutrophil\|wk_15-18 / Celltypes from embryonic and fetal-stage human lung	LILRB3 HK3 ICAM3 LILRA6 LIPN LILRB1	7.94e-06	196	107	6	36c01e0feea33448222010c21442b9fac671bd7d
ToppCell	distal-3-Hematologic-Nonclassical_Monocyte\|3 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	CDKN1C LILRB3 ICAM3 LIPN LILRB1 PPM1F	7.94e-06	196	107	6	c1f3334bc09f5d0cfb9d998a3a64f0700426a357
ToppCell	10x5'-Liver-Myeloid_Monocytic-Nonclassical_monocytes\|Liver / Manually curated celltypes from each tissue	CDKN1C HK3 LIPN PAPSS2 LILRB1 MYOF	8.17e-06	197	107	6	b0b4a704e1137f48e2258df17285ed89684ae98d
ToppCell	10x5'v1-week_12-13-Myeloid_neutrophil-granulo-neutrophil-neutrophil\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	LILRB3 HK3 ICAM3 LILRA6 LILRB1 SDCBP	8.17e-06	197	107	6	8dd10962b6ba587512b2e68c762ade68c751cbc8
ToppCell	COVID-19_Severe-Myeloid-Non-classical_Monocyte\|COVID-19_Severe / Disease group, lineage and cell class	CDKN1C PAPSS2 LILRB1 MYOF PPM1F ALDH3B1	8.17e-06	197	107	6	c5837b9a5a39a0f607a4e217ade9fc87d82a5406
ToppCell	10x5'-bone_marrow-Myeloid_Monocytic-Nonclassical_monocytes\|bone_marrow / Manually curated celltypes from each tissue	CDKN1C HK3 PAPSS2 LILRB1 MYOF ALDH3B1	8.17e-06	197	107	6	dcf1e74b7c21466d38d68f44d404bce14ade2805
ToppCell	PBMC-Severe-Myeloid-Non-classical_Monocyte-Non-classical_Monocyte\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CDKN1C PAPSS2 LILRB1 MYOF PPM1F ALDH3B1	8.41e-06	198	107	6	9b8679b3dd8f4220d71f607b7080cb88d6e71129
ToppCell	PBMC-Severe-Myeloid-Non-classical_Monocyte-Non-classical_Monocyte-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CDKN1C PAPSS2 LILRB1 MYOF PPM1F ALDH3B1	8.41e-06	198	107	6	8b6b602ebe59b6dca6a22f17385d3160ff3ac67e
ToppCell	mild_COVID-19-Non-classical_Monocyte\|mild_COVID-19 / disease group, cell group and cell class (v2)	CDKN1C LILRB3 HK3 LILRB1 MYOF PPM1F	8.41e-06	198	107	6	d7620b8d24e04ce1c563fc0ebe1625e03fe78950
ToppCell	remission-Non-classical_Monocyte\|World / disease stage, cell group and cell class	CDKN1C LILRB3 HK3 LILRB1 MYOF ALDH3B1	8.41e-06	198	107	6	1c170655070acca00520b7cf9c510a04c0a90a8f
ToppCell	PBMC-Severe-Myeloid-Non-classical_Monocyte\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CDKN1C PAPSS2 LILRB1 MYOF PPM1F ALDH3B1	8.41e-06	198	107	6	b9030390316baf456135f85f831394e1e11ecf3e
ToppCell	PBMC-Control-Myeloid-Non-classical_Monocyte\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	CDKN1C LILRB3 HK3 PAPSS2 LILRB1 MYOF	8.41e-06	198	107	6	3bc3dbd178043deadd7eef413b2761dc003abd6e
ToppCell	PBMC-Severe-Myeloid-Non-classical_Monocyte-Non-classical_Monocyte\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	CDKN1C PAPSS2 LILRB1 MYOF PPM1F ALDH3B1	8.41e-06	198	107	6	d36a3cda7e5f385d2391e9b0dfb027d3c4549320
ToppCell	Healthy-Non-classical_Monocyte\|Healthy / disease group, cell group and cell class	CDKN1C LILRB3 HK3 LILRB1 CLIP4 MYOF	8.41e-06	198	107	6	394e5fa8998c46c6f7cd57b53f347d2029c75ae1
ToppCell	PBMC-Control-Myeloid-Non-classical_Monocyte-Non-classical_Monocyte-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	CDKN1C LILRB3 HK3 PAPSS2 LILRB1 MYOF	8.41e-06	198	107	6	9b47585653aaebd033c9b7bba93c7a7c35a4d60e
ToppCell	Tracheal-10x5prime-Immune_Myeloid-Monocytic-Monocyte_CD14\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	LILRB3 HK3 LILRA6 LIPN LILRB1 CYTH4	8.41e-06	198	107	6	4ba72ba1f0cebc93053aae72d763c33e155b6fa4
ToppCell	PBMC-Severe-Myeloid-Non-classical_Monocyte\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	CDKN1C PAPSS2 LILRB1 MYOF PPM1F ALDH3B1	8.41e-06	198	107	6	5436c3ed16e10e00c686f1ab0b0a68728a1a9985
ToppCell	PBMC-Control-Myeloid-Non-classical_Monocyte-Non-classical_Monocyte\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	CDKN1C LILRB3 HK3 PAPSS2 LILRB1 MYOF	8.41e-06	198	107	6	8b5d30312bbcabc6911ff03e5028766d77203dff
ToppCell	Control-Myeloid-Non-classical_Monocyte\|Control / Disease group, lineage and cell class	CDKN1C LILRB3 HK3 PAPSS2 LILRB1 MYOF	8.41e-06	198	107	6	ae0a51e63e2751a6d9dc0c8a3852680949173523
ToppCell	Healthy_donor-Non-classical_Monocyte\|Healthy_donor / disease group, cell group and cell class (v2)	CDKN1C LILRB3 HK3 LILRB1 MYOF PPM1F	8.41e-06	198	107	6	d4eae333fa100db3ea2d4cbe7a1d6ab14816f0e2
ToppCell	PBMC-Severe-Myeloid-Non-classical_Monocyte-Non-classical_Monocyte-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	CDKN1C PAPSS2 LILRB1 MYOF PPM1F ALDH3B1	8.41e-06	198	107	6	4f67067d8142ca11b2d80195dac8d62a8d24d52c
ToppCell	severe-Myeloid-Neutrophils_4\|Myeloid / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs	LILRB3 HK3 ICAM3 LILRA6 WDFY3 SDCBP	8.66e-06	199	107	6	50242666def13e5d4149c563ae000d6768f086f7
ToppCell	Endothelial_cells-Endothelial-A\|Endothelial_cells / lung cells shred on cell class, cell subclass, sample id	CPE PAPSS2 STAT6 MYOF NUAK1 PCDH1	8.66e-06	199	107	6	2a1424c61ddcd1fea9574f7a3ad1955387458130
ToppCell	PBMC-Convalescent-Myeloid-Non-classical_Monocyte-Non-classical_Monocyte-\|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CDKN1C LILRB3 HK3 LILRB1 MYOF ALDH3B1	8.66e-06	199	107	6	99eec995aa20ac22a8dd045382bd15a15db0b87a
ToppCell	PBMC-Convalescent-Myeloid-Non-classical_Monocyte-Non-classical_Monocyte\|Convalescent / Location, Disease Group, Cell group, Cell class (2021.03.09)	CDKN1C LILRB3 HK3 LILRB1 MYOF ALDH3B1	8.66e-06	199	107	6	aca9f75c690c6ed952bcbdc7e1e7eef7719f54ca
ToppCell	PBMC-Convalescent-Myeloid-Non-classical_Monocyte-Non-classical_Monocyte\|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CDKN1C LILRB3 HK3 LILRB1 MYOF ALDH3B1	8.66e-06	199	107	6	3e09b3c2e2c57e5248981293020d2434e898e3e1
ToppCell	PBMC-Convalescent-Myeloid-Non-classical_Monocyte-Non-classical_Monocyte-\|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	CDKN1C LILRB3 HK3 LILRB1 MYOF ALDH3B1	8.66e-06	199	107	6	ae6b4b4557c6a9223acdee2a79bc780c5916d38a
ToppCell	PBMC-Convalescent-Myeloid-Non-classical_Monocyte\|Convalescent / Location, Disease Group, Cell group, Cell class (2021.03.09)	CDKN1C LILRB3 HK3 LILRB1 MYOF ALDH3B1	8.66e-06	199	107	6	4eed28ef8c74d7131eeeabdd732a682d91e034dd
ToppCell	PBMC-Convalescent-Myeloid-Non-classical_Monocyte\|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CDKN1C LILRB3 HK3 LILRB1 MYOF ALDH3B1	8.66e-06	199	107	6	f234533254fd82b1ef2041e8405fe201d874018b
ToppCell	COVID-19_Convalescent-Myeloid-Non-classical_Monocyte\|COVID-19_Convalescent / Disease group, lineage and cell class	CDKN1C LILRB3 HK3 LILRB1 MYOF ALDH3B1	8.66e-06	199	107	6	5253948a1d7fc3da571860e14cdde4e18222e13b
ToppCell	Parenchymal-NucSeq-Immune_Myeloid-Monocytic\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	LILRB3 HK3 LIPN LILRB1 PPM1F CYTH4	8.91e-06	200	107	6	fd72fe6565e2f4885481991492d58c323ab1ad40
ToppCell	COVID-19-COVID-19_Severe-Myeloid-CD16+_Monocyte\|COVID-19_Severe / Disease, condition lineage and cell class	CDKN1C PAPSS2 LILRB1 MYOF PPM1F ALDH3B1	8.91e-06	200	107	6	58fbb7fc7159cbc417e6b457d60b7beba9b90da6
Computational	Genes in the cancer module 28.	PSMC2 PSMD4 PSMD13 PSME1	9.16e-05	32	81	4	MODULE_28
Computational	Proteasome.	PSMC2 PSMD4 PSMD13 PSME1	1.64e-04	37	81	4	MODULE_91
Drug	Pindolol [13523-86-9]; Up 200; 16.2uM; MCF7; HT_HG-U133A	IFFO1 AGPAT4 MFGE8 MYH14 TLN1 R3HDM1 POU2F3 SERPINA5 CYTH4	2.59e-07	195	103	9	6834_UP
Drug	6-Hydroxytropinone [5932-53-6]; Down 200; 25.8uM; PC3; HT_HG-U133A	CDKN1C SZT2 SPTBN2 CHD7 MFGE8 TLN1 PCDH1 PSD4	2.98e-06	195	103	8	4250_DN
Drug	Elmex	ZNF135 CLTC ENO3	3.11e-06	7	103	3	CID000008926
Drug	PH 163	MPO EPX MUC5AC	4.95e-06	8	103	3	ctd:C104857
Drug	hydroxyl radicals	MPO ISYNA1 ABCA4 HK3 CYP7A1 CYP17A1 DUSP3 AGPAT4 PON3 EPX PPM1F USP32 CLTC CHRDL1 ALDH3B1 GFM1 ENO3 SDCBP MOCOS	8.12e-06	1341	103	19	CID000000961
Drug	4-hydroxynonenal	MPO CDKN1C IL18 PSMC2 PSMD4 CPE PSMD13 PSME1 STAT6 NRK MUC5AC	9.52e-06	471	103	11	CID000001693
Drug	2,6-dichloroquinone	MPO EPX CHRDL1	1.44e-05	11	103	3	CID000012771
Drug	nitrate	MPO NCOA2 CDKN2B ISYNA1 EPX PAPSS2 CHRDL1 PKN1 CRTC2	1.97e-05	331	103	9	CID000000943
Drug	2-bromohexadecanal	MPO EPX	2.03e-05	2	103	2	CID015701742
Drug	bromine trichloride	MPO EPX	2.03e-05	2	103	2	CID003014687
Drug	AC1L22VU	MPO EPX	2.03e-05	2	103	2	CID000040008
Drug	MLD987	MPO EPX	2.03e-05	2	103	2	CID006918516
Drug	PFNA	NCOA2 CDKN1C ENO3	2.49e-05	13	103	3	CID000067821
Drug	Antazoline hydrochloride [2508-72-7]; Up 200; 13.2uM; MCF7; HT_HG-U133A	MPO MIA3 IL18 CYP17A1 SPTBN2 EPX R3HDM1	2.91e-05	194	103	7	3173_UP
Drug	Nicardipine hydrochloride [54527-84-3]; Up 200; 7.8uM; MCF7; HT_HG-U133A	MPO CDKN1C AGPAT4 PON3 TAF1 R3HDM1 CYTH4	3.10e-05	196	103	7	5397_UP
Drug	Methiazole; Up 200; 15uM; PC3; HT_HG-U133A	CDKN1C NPTX2 IFFO1 AGPAT4 ASTN1 MUC5AC CYTH4	3.10e-05	196	103	7	3796_UP
Drug	Antazoline hydrochloride [2508-72-7]; Up 200; 13.2uM; PC3; HT_HG-U133A	INPP5B DUSP3 AGPAT4 CHD7 RFX7 ZNF839 RAB2A	3.10e-05	196	103	7	7128_UP
Drug	Sulfamethoxazole [723-46-6]; Up 200; 15.8uM; MCF7; HT_HG-U133A	CDKN1C MYH14 PPM1F TLN1 PCDH1 MUC5AC PSD4	3.10e-05	196	103	7	2296_UP
Drug	Budesonide [51333-22-3]; Down 200; 9.2uM; MCF7; HT_HG-U133A	INPP5B PPM1F TLN1 PKN1 TAF1 WDFY3 PSD4	3.31e-05	198	103	7	5431_DN
Drug	Pivampicillin [33817-20-8]; Up 200; 8.6uM; MCF7; HT_HG-U133A	IFFO1 ITGA8 FBXO38 MYH14 WDFY3 PCDH1 SERPINA5	3.53e-05	200	103	7	5465_UP
Drug	A-B-W	CDKN1C ABCA4 ENO3	4.82e-05	16	103	3	CID000449201
Drug	AC1L8131	CPE CHRDL1 GFM1	4.82e-05	16	103	3	CID000370472
Drug	R165481	MPO RPS6KA4 PKN1	4.82e-05	16	103	3	CID005459348
Drug	naphthol-AS-acetate	MPO EPX CHRDL1	4.82e-05	16	103	3	CID000096045
Drug	naphthol AS-D acetate	MPO EPX CHRDL1	4.82e-05	16	103	3	CID003562787
Drug	alpha-bromo-4-chlorophenylacetic acid	LILRB3 LILRA6	6.06e-05	3	103	2	CID010490868
Drug	4-chloro-1,2-benzoquinone	MPO EPX	6.06e-05	3	103	2	CID000093145
Drug	Mfpa	TAF1 TAF1L	6.06e-05	3	103	2	CID003035615
Drug	AC1L2HYK	MPO EPX	6.06e-05	3	103	2	CID000021263
Drug	l-945	LILRB3 LILRA6	6.06e-05	3	103	2	CID000097919
Drug	4-octylphenol	CYP17A1 PAPSS2 TAF1 TAF1L	6.07e-05	47	103	4	CID000015730
Drug	AC1MON7Y	MPO EPX MUC5AC	6.98e-05	18	103	3	CID003371803
Drug	rebamipide	MPO ICAM3 CHRDL1 MUC5AC	8.38e-05	51	103	4	CID000005042
Drug	11 alpha-hydroxyprogesterone	CDKN1C CYP17A1 PKN1	9.69e-05	20	103	3	CID000092730
Drug	NSC148832	MPO EPX DHPS DCHS1 PKN1 HERC2 MOCOS	1.00e-04	236	103	7	CID000030583
Drug	4-aminoquinoline	ABCA4 DHPS GFM1	1.13e-04	21	103	3	CID000068476
Drug	AC1L2O1K	MPO EPX	1.21e-04	4	103	2	CID000125126
Drug	4-nitroestradiol	MPO EPX	1.21e-04	4	103	2	CID000233494
Drug	i0830	MPO EPX	1.21e-04	4	103	2	CID000151254
Drug	trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A	NCOA2 MYOF NUAK1 TAF1 WDFY3 PSD4	1.33e-04	172	103	6	5903_DN
Drug	Cyclosporin A [59865-13-3]; Up 200; 3.4uM; MCF7; HT_HG-U133A	MIA3 LAMB2 MYOF TLN1 TAF1 PCDH1	1.46e-04	175	103	6	3267_UP
Drug	Zuclopenthixol hydrochloride [633-59-0]; Up 200; 9.2uM; MCF7; HT_HG-U133A	ANK3 EPX PAPSS2 MYOF MFGE8 R3HDM1	1.70e-04	180	103	6	7356_UP
Drug	heme b	MPO NPTX2 CYP7A1 CYP17A1 EPX PAPSS2 CLTC NSUN5P2 CHRDL1	1.87e-04	444	103	9	CID000004973
Drug	pioglitazone	CDKN1C IL18 CYP7A1 CYP17A1 ICAM3 SLC27A1	1.92e-04	184	103	6	ctd:C060836
Drug	CI-949	MPO EPX	2.01e-04	5	103	2	CID000159562
Drug	Pummerer's ketone	MPO EPX	2.01e-04	5	103	2	CID000099055
Drug	AC1MOE91	MPO EPX	2.01e-04	5	103	2	CID003342294
Drug	isotrityrosine	MPO EPX	2.01e-04	5	103	2	CID000196044
Drug	AC1Q6QQG	MPO EPX	2.01e-04	5	103	2	CID000124376
Drug	2-chloro-1,4-dimethoxybenzene	MPO EPX	2.01e-04	5	103	2	CID000246724
Drug	cupric acetate monohydrate	LILRB3 LILRA6	2.01e-04	5	103	2	CID000165397
Drug	4-biphenylboronic acid	MPO EPX	2.01e-04	5	103	2	CID000151253
Drug	t383	MPO EPX	2.01e-04	5	103	2	CID000074847
Drug	LY 294002; Up 200; 10uM; MCF7; HT_HG-U133A	MIA3 ANK3 SZT2 PAPSS2 MYOF MYH14	2.03e-04	186	103	6	1664_UP
Drug	6-[4-[(4-ethyl-2,3-dihydropyrazin-1-yl)methyl]phenyl]-N-[(1R)-1-phenylethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine	ABCA4 NRK ENO3	2.17e-04	26	103	3	CID016040258
Drug	Piromidic acid [19562-30-2]; Down 200; 13.8uM; HL60; HT_HG-U133A	IL18 ANK3 DUSP3 TAF1 ZNF839 PSD4	2.48e-04	193	103	6	2996_DN
Drug	Colchicine [64-86-8]; Up 200; 10uM; MCF7; HT_HG-U133A	STAT6 MFGE8 ASTN1 R3HDM1 ENO3 PSD4	2.55e-04	194	103	6	3213_UP
Drug	Dipyrone [5907-38-0]; Up 200; 12uM; PC3; HT_HG-U133A	NPTX2 SZT2 AGPAT4 ITGA8 MFGE8 TLN1	2.55e-04	194	103	6	4310_UP
Drug	iodine	MPO CYP7A1 DUSP3 EPX NRXN2	2.62e-04	125	103	5	CID000000807
Drug	Hippeastrine hydrobromide [22352-41-6]; Down 200; 10uM; HL60; HT_HG-U133A	NCOA2 AGPAT4 PAPSS2 LILRB1 R3HDM1 PSD4	2.62e-04	195	103	6	2187_DN
Drug	Ethynylestradiol 3-methyl ether [72-33-3]; Up 200; 12.8uM; MCF7; HT_HG-U133A	INPP5B CLIP4 R3HDM1 RAB2A SERPINA5 PSD4	2.62e-04	195	103	6	4792_UP
Drug	Dipyridamole [58-32-2]; Down 200; 8uM; MCF7; HT_HG-U133A	NCOA2 MIA3 INPP5B FBXO38 RAB2A PSD4	2.62e-04	195	103	6	5252_DN
Drug	Sulfamerazine [127-79-7]; Down 200; 15.2uM; PC3; HT_HG-U133A	SZT2 INPP5B SPTBN2 FBXO38 CHRDL1 PCDH1	2.62e-04	195	103	6	3718_DN
Drug	Alcuronium chloride [15180-03-7]; Up 200; 5.4uM; MCF7; HT_HG-U133A	CDKN1C NPTX2 SPTBN2 PON3 STAT6 DCHS1	2.70e-04	196	103	6	4409_UP
Drug	Pentamidine isethionate [140-64-7]; Down 200; 6.8uM; HL60; HT_HG-U133A	SZT2 DUSP3 AGPAT4 WDFY3 CYTH4 PSD4	2.70e-04	196	103	6	2473_DN
Drug	Pridinol methanesulfonate salt [6856-31-1]; Down 200; 10.2uM; PC3; HT_HG-U133A	INPP5B PSMD13 PAPSS2 MYOF TLN1 ZNF839	2.70e-04	196	103	6	5860_DN
Drug	Nimodipine [66085-59-4]; Up 200; 9.6uM; MCF7; HT_HG-U133A	CDKN1C IL18 SPTBN2 MFGE8 CHRDL1 PSD4	2.70e-04	196	103	6	6480_UP
Drug	Antipyrine, 4-hydroxy [1672-63-5]; Up 200; 19.6uM; MCF7; HT_HG-U133A	CDKN1C IFFO1 INPP5B MYOF PCDH1 PSD4	2.70e-04	196	103	6	1497_UP
Drug	Diazoxide [364-98-7]; Up 200; 17.4uM; PC3; HT_HG-U133A	CDKN1C INPP5B AGPAT4 FBXO38 WDFY3 PCDH1	2.70e-04	196	103	6	2052_UP
Drug	Sisomicin sulfate [53179-09-2]; Down 200; 2.8uM; HL60; HT_HG-U133A	NCOA2 CYP17A1 PSMD13 FBXO38 MYOF MYH14	2.70e-04	196	103	6	2493_DN
Drug	11-deoxy-16,16-dimethyl Prostaglandin E2; Up 200; 10uM; MCF7; HT_HG-U133A	MPO IL18 CLIP4 MFGE8 MUC5AC CYTH4	2.77e-04	197	103	6	7514_UP
Drug	genistein; Down 200; 10uM; MCF7; HT_HG-U133A	ANK3 DUSP3 CPE NUAK1 PPM1F RAB2A	2.77e-04	197	103	6	6952_DN
Drug	Edrophonium chloride [116-38-1]; Up 200; 19.8uM; MCF7; HT_HG-U133A	MPO CYP17A1 PON3 CLIP4 MYH14 CYTH4	2.77e-04	197	103	6	5001_UP
Drug	(-)-Adenosine 3',5'-cyclic monophosphate [60-92-4]; Down 200; 12.2uM; HL60; HT_HG-U133A	ANK3 DUSP3 STAT6 MYOF MOCOS PSD4	2.85e-04	198	103	6	2969_DN
Drug	chlorpromazine hydrochloride; Down 200; 1uM; HL60; HT_HG-U133A	NCOA2 RPS6KA4 PAPSS2 STAT6 PKN1 RAB2A	2.85e-04	198	103	6	6176_DN
Drug	AG-028671 [847803-03-6]; Down 200; 10uM; MCF7; HT_HG-U133A	NCOA2 INPP5B FAN1 PCDH1 SERPINA5 PSD4	2.85e-04	198	103	6	6587_DN
Drug	Monocrotaline [315-22-0]; Up 200; 12.2uM; PC3; HT_HG-U133A	INPP5B DUSP3 SPTBN2 TAF1 ZNF839 RAB2A	2.85e-04	198	103	6	7127_UP
Drug	Iocetamic acid [16034-77-8]; Down 200; 6.6uM; MCF7; HT_HG-U133A	NCOA2 MIA3 INPP5B SPTBN2 CLIP4 ENO3	2.85e-04	198	103	6	3361_DN
Drug	Nialamide [51-12-7]; Up 200; 13.4uM; PC3; HT_HG-U133A	MPO CDKN1C SZT2 IFFO1 ITGA8 R3HDM1	2.85e-04	198	103	6	4525_UP
Drug	Isradipine [75695-93-1]; Up 200; 10.8uM; MCF7; HT_HG-U133A	FBXO38 TLN1 ASTN1 TAF1 WDFY3 PCDH1	2.85e-04	198	103	6	6508_UP
Drug	Naftopidil dihydrochloride [57149-08-3]; Down 200; 8.6uM; PC3; HT_HG-U133A	CDKN1C ISYNA1 SZT2 SPTBN2 MFGE8 PSD4	2.85e-04	198	103	6	4193_DN
Drug	Scopoletin [92-61-5]; Down 200; 20.8uM; HL60; HT_HG-U133A	DUSP3 PAPSS2 MYOF PKN1 WDFY3 R3HDM1	2.85e-04	198	103	6	3131_DN
Drug	Halofantrine hydrochloride [36167-63-2]; Down 200; 7.4uM; HL60; HT_HG-U133A	ANK3 CYP17A1 CPEB3 EPX PAPSS2 MYH14	2.85e-04	198	103	6	3130_DN
Drug	Proparacaine hydrochloride [5875-06-9]; Up 200; 12uM; MCF7; HT_HG-U133A	CDKN1C IFFO1 STAT6 CLIP4 CYTH4 PSD4	2.93e-04	199	103	6	6492_UP
Drug	N-Acetyl-DL-homocysteine Thiolactone [1195-16-0]; Up 200; 25.2uM; PC3; HT_HG-U133A	NPTX2 IFFO1 ITGA8 MFGE8 TLN1 CYTH4	2.93e-04	199	103	6	4311_UP
Drug	Famprofazone [22881-35-2]; Down 200; 10.6uM; MCF7; HT_HG-U133A	NCOA2 MIA3 INPP5B MYOF PPM1F WDFY3	2.93e-04	199	103	6	3928_DN
Drug	Khellin [82-02-0]; Up 200; 15.4uM; PC3; HT_HG-U133A	AGPAT4 CHRDL1 TAF1 R3HDM1 MUC5AC PSD4	2.93e-04	199	103	6	6641_UP
Drug	bromamine	MPO EPX	3.00e-04	6	103	2	CID000123346
Drug	5-hydroxyconiferyl alcohol	MPO EPX	3.00e-04	6	103	2	CID005282095
Drug	PPHP	MPO EPX	3.00e-04	6	103	2	CID006438577
Drug	4-methoxymandelic acid	MPO EPX	3.00e-04	6	103	2	CID000112056
Drug	DBTA	LILRB3 LILRA6	3.00e-04	6	103	2	CID000149053
Drug	pulcherosine	MPO EPX	3.00e-04	6	103	2	CID000124402
Drug	indamine	MPO EPX	3.00e-04	6	103	2	CID000010841
Drug	ammonium tartrate	MPO EPX	3.00e-04	6	103	2	CID000018352
Drug	3',4'-dehydrovinblastine	MPO EPX	3.00e-04	6	103	2	CID000151120
Drug	HC-6	CLTC DHPS	3.00e-04	6	103	2	CID003031223
Drug	Pmx-53	MPO EPX	3.00e-04	6	103	2	CID006918468
Drug	Metrizamide [31112-62-6]; Down 200; 5uM; PC3; HT_HG-U133A	SZT2 SPTBN2 ASTN1 TAF1 ZNF839 RAB2A	3.01e-04	200	103	6	4075_DN
Drug	ICI182,780; Down 200; 1uM; PC3; HT_HG-U133A	ANK3 INPP5B CHRDL1 TAF1 WDFY3 R3HDM1	3.01e-04	200	103	6	5931_DN
Disease	Infiltrating duct carcinoma of female breast	RPS6KA4 NRK PKN1	4.81e-05	21	100	3	C3165106
Disease	leukocyte immunoglobulin-like receptor subfamily A member 6 measurement	LILRB3 LILRA6	1.69e-04	6	100	2	EFO_0801767
Disease	leukocyte immunoglobulin-like receptor subfamily B member 3 measurement	LILRB3 LILRA6	1.69e-04	6	100	2	EFO_0802705
Disease	interleukin 7 measurement	LILRB1 EFHC1 DCHS1	4.83e-04	45	100	3	EFO_0008189
Disease	uterine fibroid	NCOA2 HK3 PSMD13 MTMR4 CYTH4	5.95e-04	199	100	5	EFO_0000731
Disease	asthma (is_marker_for)	MPO IL18 EPX MUC5AC	9.06e-04	126	100	4	DOID:2841 (is_marker_for)
Disease	autosomal dominant polycystic kidney disease (is_marker_for)	ITGA8 STAT6	1.01e-03	14	100	2	DOID:898 (is_marker_for)
Disease	Global developmental delay	SZT2 SPTBN2 DHPS TAF1	1.11e-03	133	100	4	C0557874
Disease	Prostatic Neoplasms	MPO NCOA2 IL18 CYP17A1 LAMB2 CHD7 MYH14 TAF1L	1.19e-03	616	100	8	C0033578
Disease	Malignant neoplasm of prostate	MPO NCOA2 IL18 CYP17A1 LAMB2 CHD7 MYH14 TAF1L	1.19e-03	616	100	8	C0376358
Disease	Urticaria	MPO IL18	1.32e-03	16	100	2	C0042109
Disease	Abnormal behavior	DHPS MED12L	1.32e-03	16	100	2	C0233514
Disease	temporal arteritis (is_implicated_in)	IL18 MFGE8	1.32e-03	16	100	2	DOID:13375 (is_implicated_in)
Disease	visfatin measurement	LILRB1 PCDH1	1.50e-03	17	100	2	EFO_0801230
Disease	cystitis (biomarker_via_orthology)	MPO IL18	1.68e-03	18	100	2	DOID:1679 (biomarker_via_orthology)
Disease	Age-related macular degeneration	ABCA4 HMCN1	1.68e-03	18	100	2	cv:C0242383
Disease	monocyte count	MPO LILRB3 ARHGAP23 SZT2 INPP5B SPTBN2 LILRA6 PSMD4 TLN1 MED12L RAB2A SDCBP	1.70e-03	1320	100	12	EFO_0005091
Disease	autism spectrum disorder (implicated_via_orthology)	CHD7 NRXN2 WDFY3 MOCOS	1.81e-03	152	100	4	DOID:0060041 (implicated_via_orthology)
Disease	energy expenditure measurement	AGPAT4 GPATCH2	2.08e-03	20	100	2	EFO_0008005
Disease	myeloperoxidase (MPO)-DNA complex measurement	MPO EPX	2.51e-03	22	100	2	EFO_0011039
Disease	lung disease (is_implicated_in)	MPO IL18	2.51e-03	22	100	2	DOID:850 (is_implicated_in)
Disease	Morbilliform Drug Reaction	MPO IL18	2.75e-03	23	100	2	C0406537
Disease	Drug Eruptions	MPO IL18	2.75e-03	23	100	2	C0011609
Disease	Sjogren's syndrome (is_marker_for)	IL18 MUC5AC	2.99e-03	24	100	2	DOID:12894 (is_marker_for)
Disease	thalamus volume	CYP7A1 RFX7 NUAK1	3.05e-03	85	100	3	EFO_0006935
Disease	interstitial lung disease (is_marker_for)	MPO IL18	3.24e-03	25	100	2	DOID:3082 (is_marker_for)

Protein segments in the cluster

Peptide	Gene	Start	Entry
FAGGAQQKRENVNPR	ABCA4	1286	P78363
RAAQLQGLGRFLQEN	ALDH3B1	26	P43353
GNEPLQRLLSDNGIN	BRPF3	891	Q9ULD4
NNGSDLPEDQLRNLF	CYTH4	221	Q9UIA0
LLEQGANPAFRNDKG	CLIP4	206	Q8N3C7
PGGVDNQELNRNSLD	CHD7	621	Q9P2D1
NFARGLDQQLPDGLV	ASTN1	761	O14525
ENNIDLQRPLQSFGQ	R3HDM1	51	Q15032
FDINNEANGIKIGPQ	RAB2A	176	P61019
LRQEEPQLAGNLAGF	RAB44	176	Q7Z6P3
GNNDGENLSAPLQFR	ISYNA1	336	Q9NPH2
RGLPFQANAQDIINF	GRSF1	406	Q12849
QRALAIYEGQLGPDN	KLC4	361	Q9NSK0
DPDVGANGQLQYRIL	DCHS1	1776	Q96JQ0
NRNLGFSPGDREENI	PAPSS2	86	O95340
LNAGGFLDLENEVNP	LIPN	16	Q5VXI9
NGQFLRPQGVAVDQE	TRIM71	791	Q2Q1W2
RPFQQGQPGDQAALF	MED12L	1901	Q86YW9
VEPLGLENGNIANSQ	MFGE8	71	Q08431
EGCNIPQNIERLNGQ	HERC2	3191	O95714
RQLLQANPILEAFGN	MYH14	236	Q7Z406
ELQAGPEAQELFGLQ	PCDH1	206	Q08174
AINQRFQDNGRALLP	EPX	336	P11678
NQRFQDNGRALLPFD	MPO	366	P05164
VQDALQQNPGAFRLA	NSUN5P2	186	Q63ZY6
PAGNFDNERLAIARQ	NRXN2	1251	Q9P2S2
AQGRAQEAEQLLRGP	LAMB2	1691	P55268
QEAEQLLRGPLGDQY	LAMB2	1696	P55268
QGPIINFNVLDDKGN	MOCOS	386	Q96EN8
QQYELDLREPALGQG	RPS6KA4	406	O75676
ERDFLQRPGQQPQAG	LILRA6	261	Q6PI73
ERDFLQRPGQQPQAG	LILRB3	261	O75022
EEGLVCRNQDQQGPF	MUC5AC	3591	P98088
GQQPDLAANEAQLLR	PSMD13	256	Q9UNM6
RAQDPDGGLNGIQNY	PCDHB10	156	Q9UN67
LDAQPVNKQGLQLGF	HK3	151	P52790
EPGNDRNGLDFNRQI	POU2F3	31	Q9UKI9
QQELVAGIPRGAQNF	ITGA8	281	P53708
RGNNRNGQLLENPRF	MTMR4	866	Q9NYA4
NLPGVDPNNEAIRNA	PIPSL	826	A2A3N6
PGGRTLQILNAQEDN	HMCN1	2626	Q96RW7
GVQGQEFLLRVEPQN	ICAM3	26	P32942
GPNLFLLQQEQQGLA	IFFO1	6	Q0D2I5
RQDLQPGEQQFAADA	FBXO38	526	Q6PIJ6
EQFNPGLRNLINLGK	BAIAP2L1	21	Q9UHR4
RNNANGVDLNRNFPD	CPN1	151	P15169
DNGNNLLPFQDRSRP	CPEB3	326	Q8NE35
ELFVAEGLFQNRQPN	CHRDL1	126	Q9BU40
QGANQGQRGQEPLAD	CDKN1C	226	P49918
LPNVNQIGSGLAEFQ	CRTC2	71	Q53ET0
NGINRIGNLLVPNEN	DHPS	161	P49366
QNQELREQLGALLGP	CCDC188	176	H7C350
GDPELNVIQNYNEGI	CYP17A1	191	P05093
AGEQFGQLGRELRAQ	F8A1;	46	P23610
FQQLLQELNQPRDGF	SERPINA5	111	P05154
QELNQPRDGFQLSLG	SERPINA5	116	P05154
DGNKLIEFNNGQREL	CENPJ	1276	Q9HC77
NAQGIDLNRNFPDLD	CPE	181	P16870
RQLLEAGADPNGVNR	CDKN2B	31	P42772
FGLGLDSPQNEIAQN	ANK3	3371	Q12955
QNREIGPNDGFLAQL	DUSP3	156	P51452
GPNDGFLAQLCQLND	DUSP3	161	P51452
GIGGDRLQFNQLSQA	EFHC1	46	Q5JVL4
QQEDLFQQPGLRSEF	INPP5B	846	P32019
LQFGANPLEFLRANQ	CYP7A1	46	P22680
GGFAPNILENNEALE	ENO3	211	P13929
GFVGENAQPILENNI	GPATCH2	456	Q9NW75
LNDQVLFIDQGNRPL	IL18	51	Q14116
APNEFQGQVIAGINR	GFM1	656	Q96RP9
EEAGAQGRPLRALQN	PPP1R18	381	Q6NYC8
NLPGVDPNNEAIRNA	PSMD4	341	P55036
GLRFGDQVLQINGEN	SDCBP	151	O00560
QLQIPRIEDGNNFGV	PSME1	136	Q06323
GGPFLLEVENNERLN	HEXA-AS1	116	Q9H8Q6
NQLNDQAGETLGPAL	LRRC74B	201	Q6ZQY2
VFLRDPQELLEGGNQ	PPM1F	411	P49593
GQAQAPQRLQGAARV	NRK	431	Q7Z2Y5
NNDFVQVDPGQVGLI	FAN1	66	Q9Y2M0
ELINQLDGFDPRGNI	PSMC2	301	P35998
NAQNQGELSPPFRRD	SZT2	1201	Q5T011
PEGSGLRIQDNNNLF	TMCO2	106	Q7Z6W1
NPGNQGRQFDVNLQV	MIA3	746	Q5JRA6
GERDFLQLAGAQPQA	LILRB1	261	Q8NHL6
LAGLQFREQEVRNQG	SCHIP1	231	P0DPB3
GQLLQALENNLFRAP	TAF1L	756	Q8IZX4
PGQLLQAFENNLFRA	TAF1	736	P21675
QEFITNLNGLRDGGN	PSD4	706	Q8NDX1
GQQPGDLNFQAGDRI	SH3YL1	296	Q96HL8
NFLQIQDFEGLQNRP	NUAK1	606	O60285
RALQAGQLENQAAPD	PKN1	186	Q16512
NAGLPGDFREVLQQR	NPTX2	151	P47972
NRLAELEEFINGPNN	CLTC	1181	Q00610
QVNDPALRGGNLFPN	NCOA2	1431	Q15596
LGNENGNLLEDPLNS	ZCCHC2	696	Q9C0B9
QRNGFGENISLNPDL	ZNF135	161	P52742
NRNLILGPGNHDQEF	WDFY3	2126	Q8IZQ1
QQQLPDGTGRDLNAA	SPTBN2	1821	O15020
VGQINQQDPLRRFDG	SLC27A1	451	Q6PCB7
AEPRQNLLQAAGNVG	TLN1	631	Q9Y490
RQQQLAGNGAPFEES	STAT6	206	P42226
QLNRGPGDINLQDER	ARHGAP23	956	Q9P227
NEQNPRAQALEISGG	PON3	91	Q15166
NLLFDPGRQQGQDDE	RFX7	1306	Q2KHR2
QNLGQGPELLIRYEN	TRBV11-3	56	A0A5A6
QGDGLIGLENQQFPA	ZNF229	161	Q9UJW7
FQAGPQLQALANLEA	ZNF839	556	A8K0R7
QILGQGPELLVQFQD	TRBV11-1	56	A0A0K0K1C0
GNEREGIPANLIQQL	TARBP1	1566	Q13395
NFRNNENPTLLGVLN	AGPAT4	231	Q9NRZ5
NGELQDSGPLAQQLA	UHRF1BP1	951	Q6BDS2
DFLNEKLQGQAPGAL	ZGPAT	416	Q8N5A5
PRFNGFQQQDSQELL	USP32	816	Q8NFA0
RGLELQPQDNNGLCD	MYOF	1561	Q9NZM1